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Pharmacologic Reversal Of Drp1-Dependent Mitochondrial Fragmentation, A 
Homeostatic Mechanism In Friedreich Ataxia 
Abstract 
Friedreich ataxia is an autosomal recessive neurodegenerative disease that presents during adolescence 
that causes dysmetria, dysarthria, and ataxia; as the disease progresses, patients develop 
cardiomyopathy, which is the typical cause of death. This disease, currently without an FDA-approved 
therapy, is characterized by deficiency in frataxin, a small mitochondrial protein that is highly conserved 
across species. GAA trinucleotide repeat expansions in the first intron of the FXN gene decrease 
transcription of this gene, resulting in lower frataxin protein levels. Frataxin participates in iron-sulfur 
cluster biosynthesis, iron chaperoning, and in maintaining iron homeostasis; thus, frataxin deficiency 
impairs the functions of proteins that are dependent upon iron-sulfur cluster prosthetic groups. Aconitase 
and Complex II of the electron transport chain, for example, rely upon iron-sulfur clusters for their roles in 
ATP synthesis. Therefore, Friedreich ataxia patients also exhibit decreased ATP levels in addition to other 
mitochondrial impairments. Investigating the effects of the disease and potential therapeutics on 
mitochondrial functioning is therefore of critical importance to develop a viable therapeutic strategy for 
this disease. Alterations to mitochondrial morphology are associated with impairments to mitochondrial 
functioning in numerous neurodegenerative diseases; investigating the morphological changes that occur 
through mitochondrial fission is therefore critical to understanding the impact of this disease on the 
mitochondria. Mitochondrial fission is executed by Drp1, a GTPase, so utilizing the specific Drp1 inhibitor 
P110 provides an invaluable tool for studying morphological changes. Additionally, mitochondrial 
morphology is greatly affected by cardiolipin, a four-tailed phospholipid that anchors the electron 
transport chain. The electrostatic interactions that are critical to cardiolipin’s functions are disrupted by 
oxidative stress, so the cardiolipin-stabilizing compound SS-31 may provide bioenergetic benefits to 
Friedreich ataxia patients. This dissertation examines the effects of Friedreich ataxia on mitochondrial 
morphology and function. It establishes that frataxin deficiency increases mitochondrial fragmentation 
that is dependent upon Drp1 activity. Furthermore, it demonstrates that SS-31 may also reverse 
fragmentation in this disease and that this compound operates on the same pathway as P110. Finally, it 
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 Friedreich ataxia is an autosomal recessive neurodegenerative disease that presents 
during adolescence that causes dysmetria, dysarthria, and ataxia; as the disease progresses, 
patients develop cardiomyopathy, which is the typical cause of death.  This disease, currently 
without an FDA-approved therapy, is characterized by deficiency in frataxin, a small mitochondrial 
protein that is highly conserved across species.  GAA trinucleotide repeat expansions in the first 
intron of the FXN gene decrease transcription of this gene, resulting in lower frataxin protein 
levels.  Frataxin participates in iron-sulfur cluster biosynthesis, iron chaperoning, and in 
maintaining iron homeostasis; thus, frataxin deficiency impairs the functions of proteins that are 
dependent upon iron-sulfur cluster prosthetic groups.  Aconitase and Complex II of the electron 
transport chain, for example, rely upon iron-sulfur clusters for their roles in ATP synthesis.  
Therefore, Friedreich ataxia patients also exhibit decreased ATP levels in addition to other 
mitochondrial impairments.  Investigating the effects of the disease and potential therapeutics on 
mitochondrial functioning is therefore of critical importance to develop a viable therapeutic 
strategy for this disease.  Alterations to mitochondrial morphology are associated with 
impairments to mitochondrial functioning in numerous neurodegenerative diseases; investigating 
the morphological changes that occur through mitochondrial fission is therefore critical to 
understanding the impact of this disease on the mitochondria.  Mitochondrial fission is executed 
by Drp1, a GTPase, so utilizing the specific Drp1 inhibitor P110 provides an invaluable tool for 
studying morphological changes.  Additionally, mitochondrial morphology is greatly affected by 
cardiolipin, a four-tailed phospholipid that anchors the electron transport chain.  The electrostatic 
interactions that are critical to cardiolipin’s functions are disrupted by oxidative stress, so the 
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cardiolipin-stabilizing compound SS-31 may provide bioenergetic benefits to Friedreich ataxia 
patients.  This dissertation examines the effects of Friedreich ataxia on mitochondrial morphology 
and function.  It establishes that frataxin deficiency increases mitochondrial fragmentation that is 
dependent upon Drp1 activity.  Furthermore, it demonstrates that SS-31 may also reverse 
fragmentation in this disease and that this compound operates on the same pathway as P110.  
Finally, it provides direction for future studies regarding mitochondrial-based therapeutic 







(S616) phospho-Drp1- Drp1 phosphorylated at residue Serine 616 
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ALS- Amyotrophic lateral sclerosis 
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CHAPTER 1- INTRODUCTION 
1.1 Friedreich ataxia 
 
 Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disease 
characterized by chronic deficiency of frataxin (FXN)1-3.  FRDA affects approximately 1:50000 
individuals, although the prevalence varies greatly between genetic populations; African and 
Asian populations have far fewer incidences of this disease than European populations4,5. FRDA 
causes dysmetria, dysarthria, ataxia, fatigue, and an unstable gait, and further complications 
often include vision loss and diabetes6-10.  Most patients develop left ventricular hypertrophy11.  
Atrophy in the cerebellum, particularly the dentate nucleus, as well as upper motor neuron 
degeneration primarily contribute to these disease features, and patients also may exhibit large 
sensory neuron degradation in the dorsal root ganglia and spinal cord8,12,13.  The typical life 
expectancy of FRDA patients is approximately 40 years, and despite growing research in 
potential therapies, there is currently no cure for the disease14-16. 
Seven exons comprise the frataxin gene (the last two of which represent alternative 
isoforms of the gene); however, intron 1 plays the most critical role in the development of 
FRDA17.  Guanine-adenine-adenine (GAA) trinucleotide repeats exist in the first intron of FXN for 
all individuals; while unaffected individuals have fewer than 40 GAA repeats, FRDA patients may 
have 70-1700 GAA repeats, and longer repeat lengths correlate with lower levels of FXN 
mRNA18.  The majority of FRDA patients have GAA repeat expansion on both alleles.  For these 
typical cases of FRDA, the length of the shorter GAA repeat inversely correlates with the age of 
disease onset as well as disease severity19,20.  Typical FRDA patients still produce functional FXN 
but exhibit approximately less than 30% the levels of FXN observed in unaffected individuals, with 
some variation in levels between different tissue types21.  While the vast majority of FRDA cases 
result from GAA repeat expansions on both chromosome, 2-5% of FRDA patients are compound 
heterozygotes in which the trinucleotide repeat expansion occurs on one allele while other 
mutation(s) exist on the other allele22-24.  The percentage of FRDA cases caused by compound 
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heterozygotic mutations is approximately the same across populations, despite the overall 
frequency of FRDA varying between different populations24,25.  
Several hypotheses exist as to why GAA repeat expansions decrease transcription of 
FXN26.  The trinucleotide repeats may result in the formation of DNA-RNA hybrid structures 
during transcription, causing RNA polymerase to detach from the DNA prematurely and may 
further expand the number of GAA repeats27,28.  Alternatively, the trinucleotide repeats may 
increase DNA methylation on CpG islands in the promoter of FXN, resulting in gene silencing29-31.  
The relationship between GAA trinucleotide repeats, FXN levels, and disease severity remains an 
important avenue of investigation for the field as the insights gained from such studies may 
elucidate potential therapeutic targets. 
 
1.2 FXN function 
 
 As FRDA is characterized by FXN deficiency, the role of this evolutionarily conserved 
protein has been widely studied and debated32-34.  FXN is a 210 amino acid nuclear encoded 
protein with an N-terminal mitochondrial targeting domain; following translation, the precursor 
FXN is imported to the mitochondria where is undergoes two cleavage events by mitochondrial 
processing peptidase, resulting in the mature form of FXN (amino acids 81-210)35,36.  The 
sequence and crystal structure are highly conserved across species including yeast (S. 
cerevisiae) and bacteria (E. coli)37,38.  This strict conservation suggests that FXN has a vital 
function in cellular operations. 
The role of FXN is inextricably linked to the cellular functions of iron.  This essential metal 
plays critical roles in numerous cellular functions including oxygen transport, neurotransmitter 
regulation, and DNA synthesis39,40.  Additionally, iron plays several critical roles in cellular 
metabolism; iron’s functions in metabolic pathways and its interactions with FXN in these 
pathways are at the crux of FRDA pathophysiology.  
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FXN primarily localizes to the mitochondrial matrix where it may bind two Fe(II) atoms41.  
Binding Fe(II) atoms suggests that FXN may play a role iron storage and thus protect the cell 
from iron overload; however, this function is redundant of mitochondrial ferritin42.  The primary 
role of FXN, therefore, lies in biosynthesis of iron-sulfur clusters (ISC), prosthetic groups critical 
for numerous mitochondrial enzymes.  Frataxin knockout results in intramitochondrial iron 
accumulation as well as deficiency in ISC-containing enzymes, like aconitase and Complexes I 
and II of the ETC43-45.  Thus, FXN deficiency in FRDA leads to intramitochondrial iron 
accumulation and decreases ISC biosynthesis, resulting in impaired mitochondrial functioning.  
 
1.3 Electron transport chain in functional mitochondria 
 
 The electron transport chain (ETC) generates an electron gradient across the inner 
mitochondrial membrane (IMM) that is used for ATP synthesis.  The ETC is comprised of four 
major multi-protein complexes: NADH-ubiquinone oxidoreductase, succinate dehydrogenase, 
ubiquinol-cytochrome c oxidoreductase, and cytochrome c oxidase (Complexes I-IV 
respectively)46.  These four complexes are anchored to the IMM while two mobile components, 
coenzyme Q and cytochrome c, facilitate electron transfer across the four complexes46.  ATP 
synthase (Complex V) utilizes the electron gradient generated by the ETC to synthesize ATP 
through oxidative phosphorylation, and this mechanism is the cell’s primary method of generating 
ATP46. 
 Complexes I and II of the ETC, as well as aconitase in the TCA and numerous other 
enzymes, rely upon iron-sulfur clusters (ISCs) to function47.  These prosthetic groups may take on 
various structures, often bind to cysteine residues, and are highly conserved across species47.  
These bioinorganic molecules efficiently transfer electrons across proteins; this property allows 
ISCs to serve a variety of functions in metabolism, DNA repair, and other critical cellular 
pathways47.  ISC biosynthesis impairment in FRDA is detrimental because of the ISC ubiquity in 
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critical cellular processes.  This dissertation will investigate the mitochondrial dysfunction 
resulting from FXN deficiency and the subsequent ISC biosynthesis impairment in FRDA. 
 
1.4 Mitochondrial dysfunction and fragmentation in neurodegenerative disease 
 
 Mitochondria are highly dynamic organelles that alter their morphology in response to 
various environmental and cellular stressors48-53.  While a correlation exists between 
mitochondrial morphology and metabolic functioning, the precise metabolic effects of altered 
morphology are dependent upon the tissue type and disease state.  Generally, however, the 
mitochondria of healthy cells fuse into elongated, tubular structures54,55.  When a cell experiences 
stress, particularly oxidative stress or accumulation of reactive oxygen species (ROS), the 
mitochondria fragment, forming punctate structures.  In certain tissue types and disease states, 
this fragmentation may represent a homeostatic response intended to target dysfunctional 
mitochondria for mitophagy or to increase the overall mitochondrial surface area56-58.   
In numerous disease states, however, excessive mitochondrial fragmentation appears to 
be a detrimental consequence of disease.  Particularly in neurodegenerative disease like 
Parkinson disease (PD) and Amyotrophic lateral sclerosis (ALS), mitochondrial fragmentation 
results in impaired metabolic functioning59,60.  In these and many other diseases in which 
mitochondrial fragmentation has been studied, however, mitochondrial fragmentation represents 
a secondary disease feature, downstream of the primary cause of disease.  Contrast this with 
FRDA, a disease with mitochondrial dysfunction as the immediate consequence of frataxin 
deficiency.  Therefore, while mitochondrial fragmentation may be detrimental in diseases where 
mitochondrial dysfunction is a secondary feature, mitochondrial fragmentation may represent a 
homeostatic response in FRDA and other diseases with mitochondrial dysfunction as a primary 
consequence of the disease.   
The GTPase Dynamin-related protein 1 (Drp1) executes mitochondrial fragmentation 
(Fig. 1.4.1).  When phosphorylated at its Serine 616 residue (S585 in rats) by cyclin-dependent 
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kinase 1 (CDK1) or CDK561,62, (Ser616) phospho-Drp1 is chaperoned to the mitochondria by the 
protein myeloid cell leukemia 1 (Mcl1)63.  (Ser616) phospho-Drp1 homo-oligomerizes and binds 
to adaptor proteins including mff, fis1, MiD49, and MiD5164.  This typically occurs at mitochondrial 
associated membranes (MAMs) which are contact points between the mitochondria and the 
endoplasmic reticulum (ER)65,66.  In addition to adapter proteins, the four-tailed phospholipid 
cardiolipin (CL) facilitates (Ser616) phospho-Drp1 binding to and fragmenting the 
mitochondria67,68.  The oligomerized (Ser616) phospho-Drp1 forms a ring surrounding the 
mitochondria and mechanically severs this organelle through GTPase activity69.  The (Ser616) 
phospho-Drp1 then dissociates from the mitochondria and may undergo other post-translational 







Fig. 1.4.1 Visual representation of mitochondrial fragmentation.  Unmodified Drp1 is dispersed in 
the cytosol (A).  CDK1 phosphorylates Drp1 at Ser616, causing in (Ser616) phospho-Drp1 to be 
chaperoned to the mitochondria where this protein homo-oligomerizes (B).  Through GTPase 
activity, (Ser616) phospho-Drp1 mechanically severs the mitochondria (C).  Individual 
mitochondrial fragments result, and (Ser616) phospho-Drp1 dissociates from the mitochondria 
(D).  A representative immunofluorescence ICC image of (Ser616) phospho-Drp1 localized to 






Reversing mitochondrial fragmentation is currently a highly studied approach for treating 
neurodegenerative diseases; a primary goal of this thesis is to determine whether such an 
approach is viable for treating FRDA or if fragmentation is a beneficial, homeostatic response in 
this disease. 
 
1.5 P110 and SS-31 as potential therapies for neurodegenerative disease 
 
 Peptide 110 (P110) is a small peptide that inhibits the GTPase activity of Drp1 and 
prevents (Ser616) phospho-Drp1 from binding to the mitochondria70.  To improve transport of this 
peptide into the cell, a cell-penetrating TAT domain may be added to the N-terminus of P110.  At 
concentrations at or below 1 µM, P110 reverses mitochondrial fragmentation, improves 
mitochondrial functioning, inhibits ROS production, and is neuroprotective in models of Parkinson 
Disease (PD), Huntington Disease (HD), and Multiple Sclerosis (MS)71-73.  Additionally, Drp1 
inhibition ameliorates several pathologic hallmarks of Alzheimer Disease (AD)74.  P110 treatment, 
moreover, reverses mitochondrial fragmentation and improves cellular bioenergetics in several 
cardiomyopathy disease models75,76.  Despite extensive investigation in other neurodegenerative 
diseases, the effects of P110 on mitochondrial morphology and metabolic function have not 
previously been studied in sub-acute or chronic models of FRDA. 
 Szeto-Schiller compound 31 (SS-31) is a small peptide that stabilizes cardiolipin, 
although the mechanisms by which SS-31 performs this function as well as the nature of this 
stabilization are not yet fully defined77.  Cardiolipin is a four-tailed phospholipid that predominantly 
localizes to the inner mitochondrial membrane (IMM) and plays critical roles in both mitochondrial 
bioenergetics and apoptosis78-80.  The steric structure of cardiolipin forms cristae in the IMM, 
brings the complexes of the ETC in close proximity, and anchors cytochrome c.  Exposure to 
certain stressors, particularly oxidative stress, disrupts the electrostatic interactions binding 
cardiolipin to these proteins, resulting in impaired ETC functioning and cytochrome c release 
leading to apoptosis81.  SS-31 may prevent disruption of these electrostatic interactions or 
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otherwise prevent lipid peroxidation to increase ATP synthesis and prevent cytochrome c 
release82. 
 SS-31 is neuroprotective and improves cellular respiration in several disease models83,84.  
Additionally, SS-31 reverses excessive mitochondrial fragmentation is models of mitochondrial 
cardiomyopathies85,86.  SS-31 increases the level of frataxin and decreases ROS accumulation in 
one FRDA patient-derived lymphoblast cell line87. 
A primary goal of this dissertation is to compare the effects of TAT-P110 and SS-31 on 
mitochondrial morphology and function across sub-acute and chronic cellular models of FRDA.  
This thesis will investigate whether the effects of SS-31 are dependent upon Drp1 activity and 
whether SS-31 and TAT-P110 affect the same cellular pathway.  Additionally, this thesis will 
explore the effects of mitochondrial fragmentation in FRDA, whether mitochondrial fragmentation 
may be reversed by these peptides, and whether mitochondrial fragmentation represents a viable 
therapeutic target for the treatment of FRDA. 
 
1.6 Nrf2 involvement in disease state 
 FRDA patient cells have an impaired ability to cope with oxidative stress, typically leading 
to ROS accumulation and may increase susceptibility to DNA damage and cell death.  Typically, 
when a cell experiences oxidative stress, nuclear factor erythroid 2-related factor 2 (Nrf2) is 
upregulated88.  This master transcriptional regulator promotes expression of antioxidant response 
element (ARE) genes.  ARE expression allows the cell to successfully reduce the accumulated 
ROS, so Nrf2 is highly upregulated in many disease states in which the cell would otherwise 
experience oxidative stress.  However, in FRDA, Nrf2 is paradoxically decreased89,90. 
Although the heart is susceptible to oxidative damage, antioxidant enzyme activity is 
lower in cardiac tissue than in other tissues91.  Because oxidative stress contributes to many 
common forms of cardiac dysfunction, Nrf2 activators may be useful in counteracting the 
oxidative damage resulting from cardiac diseases92.  This function may prove particularly 
beneficial in FRDA since cardiac dysfunction is the typical cause of death for this disease.  
9 
 
Moreover, ferroptosis, an iron-dependent form of cell death that occurs independently of 
apoptosis, relies upon oxidation of polyunsaturated fatty acids (PUFAs) and may play a role in 
neurodegenerative diseases93.  Nrf2 activation may therefore counteract ferroptosis by limiting 
lipid peroxidation93.  Ferroptosis is a pathogenic mechanism in FRDA, and ferroptosis inhibitors 
appear to be beneficial in suppressing this pathway in FRDA cellular models94.  Nrf2 activating 
drugs may therefore also prove beneficial by inhibiting ferroptosis in FRDA patients.   
In addition to its antioxidant activity, Nrf2 also plays a critical role in suppressing chronic 
inflammation, a pathogenic feature in a number of neurodegenerative diseases.  Toll-like 
receptors (TLRs) signal for increased production of cytokines, chemokines, and interferons in 
response to various environmental stressors and endogenous pro-inflammatory stimuli95.  While 
this inflammation response may represent a homeostatic mechanism acutely, chronic activation 
of this pathway becomes detrimental for the cell95.  Moreover, chronic inflammation is associated 
with numerous neurodegenerative diseases, including Multiple Sclerosis, Alzheimer Disease, and 
Parkinson Disease96,97.  This chronic inflammation appears to result from disruptions to regulatory 
mechanism, and therefore, pharmacologic regulation of inflammation may prove beneficial for 
ameliorating the effects of chronic inflammation in neurodegenerative diseases.  Nrf2 activation 
suppresses inflammation by inhibiting transcription of pro-inflammatory cytokine genes98.  
Although the antioxidant activity of Nrf2-target genes may also improve the cell’s ability to 
respond to chronic inflammation be reducing free radicals, this transcriptional regulation of pro-
inflammatory signals is independent of Nrf2 redox control98. 
 
1.7 Approaches to upregulating Nrf2 
Nrf2-activating drugs are therefore undergoing investigation for potential use in treating 
FRDA.  One mechanism of action for Nrf2-activating drugs is inhibiting the interaction between 
Nrf2 and Keap1, an E3 ubiquitin ligase that targets Nrf2 for degradation99.  This is the mechanism 
of action for drugs like omaveloxolone100.  However, Nrf2 protein levels may be regulated 
independently of Keap1; Hrd1 (synoviolin), another E3 ubiquitin ligase, ubiquitinates Nrf2, as well 
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as other mitochondrial biogenesis proteins, independently of Keap1 activity101,102.  LS-102, an 
Hrd1 inhibitor, may consequently upregulate Nrf2102-104. 
 As KEAP1 appears to be the most critical regulator of Nrf2 levels, alterations to KEAP1 
expression and/or activity consequently impact Nrf2.  KEAP1 hypermethylation silences this gene 
resulting in Nrf2 accumulation105.  Moreover, several small molecules that inhibit the interaction 
between KEAP1 and Nrf2 have also been developed106.  Preventing this interaction thus prevents 
Nrf2 degradation, causing further accumulation of this protein. 
Several cysteine residues on KEAP1 perform a redox-sensing function on this protein106.  
Because these residues are susceptible to electrophilic attack and modification, they make 
appropriate targets for pharmacologic KEAP1 inhibitors.  In addition to RTA-408, bardoxelone 
methyl, and dimethyl fumarate, several other drug candidates that electrophilically modify KEAP1 
cysteine residues are currently at various phases in clinical trials for neurodegenerative and 
neurologic diseases, various cancers, and diabetes106. 
In addition to ubiquitylation by KEAP1, micro-RNAs (miRNAs) also post-transcriptionally 
regulate Nrf2 levels107.  Numerous short, single-stranded miRNAs negatively regulate Nrf2 
expression in reticulocytes and cancer cells108-110.  Utilizing such miRNAs may prove to be an 
useful therapeutic strategy as an alternative or supplement to KEAP1 inhibition. 
Nrf2 activity may also be regulated through alterations to its subcellular localization.  
Progerin protein sequesters Nrf2 outside the nucleus, and this cytosolic localization impairs Nrf2 
activity111.  Progerin is constitutively expressed in patients with Hutchinson-Gilford progeria 
syndrome, so Nrf2 activity impairment resulting in increased oxidative damage may represent a 
mechanism for disease pathogenesis111,112. 
 
1.8 Materials and Methods 
Cell culture 
 Skin fibroblasts were derived from 5 FRDA patients and 1 healthy control.  These 
fibroblasts were cultured in DMEM/F12 medium containing 1% Penicillin/Streptomycin, 1% non-
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essential amino acids, and 10% fetal bovine serum; the antibiotics were omitted for experiments 
involving transfection as the combination of reagents may be toxic to the cells.  Cell cultures were 
maintained in 10cm plates; experiments were performed in 12-well plates.  24 hours prior to an 
experiment, cells were seeded at a density of 5x104 cells/well in a 12-well plate.  The cells were 
incubated at 37°C with 5% CO2.   
siRNA knockdown 
 The cell culture conditions listed above were followed.  The sequence for FXN-targeting 
siRNA is GAACCUAUGUGAUCAACAAGCAGAC (Integrated DNA Technology), and the non-
targeting control is Stealth RNAi siRNA Negative Control (Invitrogen, 12935100).  siRNA 
transfection was performed 24 hours after plating the cells.  2.5 µL of 20 µM siRNA and 5 µL 
Lipofectamine RNAi Max were combined with 275 µL of Opti-MEM, and the mixture was 
incubated at room temperature for 10 minutes.  85 µL of this mixture were then added to each 
well, and the transfected cells were incubated at 37˚C with 5% CO2 for 72 hours.  At this time, 
lysates were collected for Western blots, cells were mounted to coverslips for 
immunocytochemistry (ICC), or the ATP assay was performed (see relevant subsections in 
Materials and Methods for further details). 
SS-31 in cell culture 
 SS-31 was provided by Stealth BioTherapeutics.  The drug was reconstituted in sterile 
water to a concentration of 1mM; this stock solution and aliquots of various working 
concentrations were stored at -20° C until use.  24 hours after plating, cell cultures were treated 
with 1 µM SS-31 or water as the vehicle control for 72 hours. 
TAT-P110 
 TAT-P110 and an inactive, scrambled form of this peptide were obtained from Genscript.  
The sequence of TAT-P110 is as follows: YGRKKRRQRRRGGDLLPRGT with C-terminal 
amidation.  The sequence of scrambled TAT-P110 is as follows: YGRKKRRQRRRGGTLGRLPD 
with C-terminal amidation.  Both of these peptides contain the cell-penetrating TAT sequence on 
the N-terminal (amino acid residues 1-13 in the sequences listed above).  Drug treatment began 
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24 hours after plating.  Cell cultures were treated with 1 µM TAT-P110 or 1 µM scrambled peptide 
for 72 hours.  For experiments involving the combination of SS-31 and TAT-P110, cells were 
simultaneously treated with 1 µM SS-31 and 1 µM TAT-P110 for 72 hours. 
Cell lysate preparation 
 RIPA buffer (150mM Sodium chloride, 1mM EDTA, 100 mM Tris-HCl pH 7.4, 1% Triton-X 
100, 0.5% Sodium deoxycholate, and on the day of use 1:500 EDTA-free protease inhibitor 
cocktail III) was used for cell lysis.  150 µM RIPA buffer were added to each well of the plate.  
The wells were vigorously scraped for 30 sec., and the resulting cell lysates were collected in 
microcentrifuge tubes.  The cell lysates were stored at -20° for less than one week before 
Western blot analysis. 
Antibodies 
-actin (Abcam, Cell Signaling Technology, 3700S, 1:1000 for WB), -Drp1 
(Abcam, ab184247, 1:250 for ICC, 1:1000 for WB), α-phospho Drp1(S616) (Cell Signaling 
Technology, 3455S, 1:250 for ICC, 1:1000 for WB), α-FXN (Abcam, ab110328, 1:1000 for 
WB), -GRP75 (Abcam, ab2799, 1:250 for ICC). 
Western blot analysis 
 The protein concentration in cell lysates was quantified using the Pierce BCA Protein 
Assay Kit (Thermo Fisher Scientific catalog #23225) following the included protocol.  A volume of 
cell lysate necessary for 20 µg of protein was mixed with 2µL NuPAGE 10x sample reducing 
agent (Thermo Fisher catalog #NP0009), 5µL NuPAGE 4x LDS sample buffer (Thermo Fisher 
catalog #NP0007), and sterile water to a total volume of 20 µL.  Samples were then added to 
each well of a 10-, 12-, or 15-well NuPAGE 4-12% Bis-Tris polyacrylamide gel, and 5 µL of Bio-
Rad Precision Plus Dual Colored Standards was added to one well.  MES SDS Running Buffer 
was added to the apparatus, and the gel was run at 120V for 1 hour 30 minutes.  The proteins 
were transferred to a 0.45 µm nitrocellulose membrane using a wet transfer apparatus running at 
95V for 1 hour 15 minutes.  Following transfer, the membrane was blocked for one hour at room 
temperature using 3% milk diluted in TBS-T.  The membrane was incubated with the listed 
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dilution of primary antibody overnight at 4°C, then washed 3 times (5-10 minutes each) with TBS-
T, and finally incubated with the listed dilution of secondary antibody (appropriate to the species 
from which the primary antibody was isolated) for 1 hour at room temperature.  The membrane 
was washed 3 times (5-10 minutes each) with TBS-T then incubated with 2µL Pierce ECL 
Western blotting substrate (Thermo Fisher catalog #32106).  The ECL substrate was removed, 
and the blot was imaged using a camera apparatus designed to capture ECL.  Protein levels 
were quantified using ImageJ software (NIH).  3-5 replicates for each experiment were quantified 
in this way. 
ATP level assay 
 The CellTiter-Glo Luminescent Cell Viability Assay (Promega, G7570) was utilized to 
assess the relative level of ATP in fibroblasts.  5x104 cells were seeded in each well of a 12-well 
plate, following the above cell culture protocol.  After the appropriate drug treatment, media was 
removed and 500 µL 0.05% trypsin was added to each well until the cells detached from the 
plate.  The cells were centrifuged at 1000 rcf for 10 minutes and resuspended in 1mL cell culture 
media.  5x103 cells were added to each well of a 96 well plate, and the included protocol included 
with the assay kit was performed as written.  Luminescence was measured using a Synergy 2 
Multi-Mode microplate reader using the CellTiter-Glo protocol with a 0.5 sec. integration time.  
The amount of luminescence was recorded, serving as a proxy for the relative ATP level. 
Immunocytochemistry and immunofluorescence imaging 
 A 1cm round glass coverslip was added to each well of a 12-well plate.  Fibroblasts were 
then seeded in each well following the appropriate cell culture and treatment conditions as listed 
above.  After treatment, media was removed and cells were fixed with 4% paraformaldehyde in 
PBS for 10 minutes at 4°C.  5% normal goat serum, 1 % bovine serum albumin, and 0.3% 
(vol/vol) Triton X-100 in PBS at room temperature for 1 hour.  The coverslips were then incubated 
with primary antibodies to GRP75 (mitochondrial marker) and (Ser616) phospho-Drp1 at the 
dilution listed above at 4°C overnight.  After 3 washes (5-10 minutes each) in PBS, the coverslips 
were incubated with secondary antibodies (to the species from which the primary antibodies were 
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isolated) conjugated to Alexa Fluor 488 or 568 (Invitrogen) at room temperature for 1 hour 30 
minutes.  After 3 washes (5-10 minutes each) in PBS, the coverslips were mounted to slides 
using Vectashield with DAPI (Vector Laboratories).  Fluorescence images were obtained with 
Leica DM6000 microscope.  The slides were sequentially imaged for (Ser616) phospho-
Drp1 and GRP75 staining. 
Quantification of Mitochondrial Fragmentation 
 The field’s previously standard method for quantifying mitochondrial fragmentation 
involved a blinded individual counting the number of cells in fluorescence images that appeared 
to have tubular or punctate mitochondria.  While statistically significant preliminary results were 
obtained using this method, it lacks a high degree of objectivity, rigor, and reproducibility.  To 
combat this, the author of this dissertation developed a novel method of quantifying mitochondrial 
fragmentation that improves upon rigor and reproducibility and that provides a more quantitative 
result for such experiments. 
A confocal immunofluorescence image of cells stained for a mitochondrial marker is 
imported to ImageJ software (NIH) and is converted to a black and white image.  A threshold is 
set to eliminate background noise, and this setting is kept constant for all images analyzed within 
an experiment.  A single cell is demarcated using the polyhedron line tool, and the software 
quantifies the number of mitochondrial fragments within the demarcated area (a mitochondrial 
fragment is denoted as group of black pixels surrounded by white pixels).  Fig. 1.8.1 offers a 
visual representation of this quantification method. 
A minimum of 30 cells from each of 3 (healthy) or 9 (FRDA) biological replicates were 
quantified using the previously standard method.  A minimum of 20 cells per group from each of 
2-3 biological replicates (each with 3 technical replicates) were quantified using the novel method. 
Validation of novel method 
To validate this novel method of quantifying mitochondrial fragmentation, results were 
analyzed using both the previous and the novel methods.  The results of this novel method 
parallel the results of the previously standard method (Fig. 1.8.2).  Reference sections 2.3 and 
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2.4 for the full experimental designs and data used in making this comparison.  The results of 
using these two methods are highly similar validating this novel method as a reliable tool by which 
to quantify mitochondrial fragmentation.  Because the novel method is more quantitative, more 
rigorous, more reproducible, and less time consuming, this method was used throughout this 
dissertation.  The author recommends other groups use this method for experiments requiring the 
quantification of mitochondrial fragmentation. 
(Ser616) phospho-Drp1 cluster quantification 
 The number of (Ser616) phospho-Drp1 clusters per cell were quantified in much the 
same way as the number of mitochondrial fragments (see above).  The only exception is that 
fluorescence images of (Ser616) phospho-Drp1 staining were imported to ImageJ.  In this 
method, a (Ser616) phospho-Drp1 cluster is denoted as a group of black pixels surrounded by 
white pixels.  The number of (Ser616) phospho-Drp1 clusters per cell were quantified for at least 
20 cells from each of 3 biological replicates (each with 3 technical replicates). 
Mouse Model 
 All experiments performed on mouse models adhered to an IACUC-approved protocol.  
The Knock in/Knockout (KIKO) mouse model (Jackson Laboratories #012329 B6.Cg-
Fxn(tm1.1Pand) Fxn(tm1Mkn/J)) has one null FXN allele and a humanized expansion sequence 
in the second FXN allele.  This model exhibits mitochondrial deficits, decreased levels of 
mitochondrial proteins, and neurobehavioral deficits consistent with FRDA patients113-115.  The 
results of this compound heterozygote model were compared to the Knock in/Wild type (KIWT) 
control.  This control model has one wild type FXN allele and a humanized expansion sequence 
in the second FXN allele. 
SS-31 in Mouse Model 
 24 mice (12 KIWT and 12 KIKO) were used for these experiments with even numbers of 
male and female mice in each group.  Half of the mice were subcutaneously injected with 5 mg 
SS-31 per 1 kg bodyweight while the other half were injected with the same amount of saline 
solution as a vehicle control.  The mice were approximately 3 months of age at the start of the 
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experiments.  The mice were injected for 5 consecutive days, followed by 2 days without 
injections, and 5 more consecutive injection days.  Mice were sacrificed via isoflurane and 
decapitation approximately 2 hours after the final injection.  Tissues were harvested immediately.  
The cerebella were homogenized using RIPA buffer and prepared for Western blot analysis 
following the previously outlined protocol. 
Transcript level analysis 
 RNA transcript levels from fibroblasts derived from 17 healthy control individuals and 18 
FRDA patients were assessed by interrogating the publicly accessible dataset GSE104288, 
available on the NCBI Gene Expression Omnibus116.  The transcript levels were previously 
normalized for analysis following RNA sequencing, and the levels of 16531 gene transcripts were 
reported116.  R programming language and tidyverse packages were used to write a script that 
interrogates this database for the transcript levels of genes relevant to mitochondrial dysfunction 
in FRDA (Appendix).  To validate the functionality of this code in conjunction with the RNA-seq 
database, the level of FXN transcripts was assessed; in accordance with well-established 
literature, the script confirms decreased FXN transcript levels in FRDA patients (Appendix). 
Statistical Analysis 
All experiments were performed according to a preset plan, including the number of 
replicates.  Graphs display the mean of the data ± S.E.M.  Mitochondrial fragmentation and 
(Ser616) phospho-Drp1 clustering were analyzed using two-tailed, independent samples t-test.  
Western blot quantifications and ATP assay results were analyzed in R using Wilcoxon rank-sum 









Fig. 1.8.1 Novel method for quantifying mitochondrial network fragmentation.  An 
immunofluorescence ICC cell culture image is imported to ImageJ (A).  The color channels are 
split such that only the channel for mitochondrial staining is displayed, in this case the green 
channel (B).  A threshold is set to eliminate background (C).  A single cell is demarcated using 
the polygon tool (D).  The number of particles (defined as a group of black pixels surrounded by 
white pixels) is quantified (E).  This is the number of mitochondrial fragments per cell and may be 





Fig. 1.8.2 Validation of novel method for quantifying mitochondrial network fragmentation.  The 
field’s previously standard method for quantifying mitochondrial fragmentation involved a blinded 
individual counting the number of cells that appear to have fragmented or tubular mitochondria, 
and the resulting data shows a percentage of cells with fragmentated mitochondria.  This method 
shows an increased percentage of cells with fragmented mitochondria (A-B).  The same 
experiments were repeated but were quantified using the author’s novel method, and the results 
show an increased number of mitochondrial fragments per cell (C-D).  The parallel results 
validate the author’s novel method as a less time-consuming and more quantitative means of 





CHAPTER 2- CELL VIABILITY AND MITOCHONDRIAL MORPHOLOGY IN SUB-ACUTE AND 




 The progressive nature of FRDA inherently suggests that pathologies may differ across 
different stages of disease.  Cells in early stages of disease progression may exhibit drastically 
different phenotypes from those in later stages.  It therefore becomes critical to compare sub-
acute and chronic models of FRDA to gain insights into differential pathway expression across 
disease progression. 
 Numerous neurodegenerative disease models exhibit excessive mitochondrial 
fragmentation; additionally, a yeast model of FRDA also exhibits fragmentated mitochondria117.  
However, mitochondrial fragmentation has not previously been investigated across sub-acute and 
chronic models of FRDA in human fibroblasts.  Moreover, mitochondrial fragmentation has not 
previously been causally linked to FXN deficiency through knockout/restoration experiments. 
The goal of this chapter is to demonstrate the effects of sub-acute and chronic FXN 
deficiency on mitochondrial fragmentation in human cells.  To begin a pathway analysis and 
investigate the effects on metabolism, this chapter also examines the effects of sub-acute and 
chronic FXN deficiency on levels of proteins relevant to this area of investigation as well as the 
effects on overall ATP levels.  The results of these experiments begin to reveal the relationship 
between FXN deficiency, mitochondrial fragmentation, and ATP levels in sub-acute and chronic 
models of FRDA. 
 
2.2. Introduction 
 FXN is differentially expressed in a tissue-specific manner during development, with the 
highest levels in the spinal cord and dorsal root ganglia118.  That FXN deficiency in FRDA 
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drastically impacts these tissues is therefore unsurprising; however, this observation during 
development additionally speaks to the progressive nature of FRDA.  The prenatal impacts of 
such dysregulated protein expression alter development, and the disease progressively 
intensifies throughout the course of a patient’s life119,120.  Therefore, investigating both the 
immediate response and the long-term effects of FXN deficiency is critical to understanding the 
molecular response to this insult.  This dissertation thus utilizes both sub-acute and chronic 
models of FRDA to differentiate between the initial response to FXN deficiency and the pathway 
alterations resulting from the chronic disease. 
 To examine the cell’s immediate response to FXN loss, siRNA-mediated FXN knockdown 
provides an invaluable tool.  Examining how the cell responds to this insult reveals the 
homeostatic mechanisms the cell utilizes in an attempt to accommodate for this stress.  In 
addition to providing increased understanding of FXN’s role in cellular functions, this model may 
also reveal potential therapeutic targets for FRDA. 
Contrast this sub-acute model to FRDA patient-derived fibroblasts; in this model cells 
exhibit chronic FXN deficiency in the same capacity as patients by the time the present at clinic.  
Fibroblasts provide a relatively non-invasive method for studying patient-derived tissue.  
Investigating these cells may reveal the long-term alterations to molecular pathways that result 
from the cell attempting to maintain homeostasis throughout the chronic insult of FRDA.  
Transfecting FRDA patient-derived fibroblasts with exogenous FXN then demonstrates which 
cellular phenotypes may be reversed by restoring FXN levels.  While certain disease phenotypes 
may be reversed by FXN re-expression, other pathways may be too drastically altered such that 
FXN restoration is incapable of restoring the healthy phenotype. 
The results of FXN knockdown in conjunction with the results of FXN re-expression 
provide further insight into the disease pathologies that are dependent upon FXN levels.  The 
combination of these results may demonstrate which pathway dysregulations are directly caused 
by FXN deficiency.  Comparing these results to those from the patient-derived fibroblasts 
provides insight into which mechanisms represent an initial response to the insult of FXN loss and 
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which mechanisms are long-term consequences and alterations resulting from chronic FXN 
deficiency. 
While fibroblasts provide an efficient and valuable model for studying these pathway 
alterations, limitations exist that are inherent to in vitro experiments.  The cell culture environment 
does not fully imitate the environment of cells in the body.  Interactions with other tissue types 
may alter the cellular response to sub-acute and chronic FXN deficiency as well as FXN 
restoration.  Thus, the results of in vitro models may not be extrapolated to the organismal level.  
Additionally, fibroblasts are only one tissue type while FRDA is a multi-system disorder.  The 
results from fibroblasts may not necessarily be consistent throughout all tissue types.  Despite 
these limitations, these fibroblast models do provide critical information on cellular responses in 
FRDA.  The data gathered from such in vitro experiments may later guide work in vivo. 
This chapter thus incorporates sub-acute, chronic, and FXN restoration models of FRDA 
to differentiate between these molecular alterations.  It investigates protein levels, ATP levels, the 
amount of mitochondrial fragmentation, and the amount of (Ser616) phospho-Drp1 clusters as 
biomarkers of disease state and differential pathway regulation in each model. 
 
2.3 Frataxin knockdown 
 To determine the effects of sub-acute FXN deficiency on mitochondrial morphology and 
function, fibroblasts derived from healthy individuals were transfected with siRNA targeted to 
FXN.  This siRNA-mediated FXN knockdown resulted in 0.36 times the level of FXN observed in 
fibroblasts transfected with an empty vector (Fig. 2.3.1).  FXN knockdown in this model did not 
alter the total levels of Drp1 or (Ser616) phospho-Drp1 protein (Fig. 2.3.2); however, the level of 
Mc1 was significantly increased to 3.9 times the level in controls (Fig. 2.3.3).  FXN knockdown 
significantly increased the number of mitochondrial fragments (Fig. 2.3.4) and (Ser616) phospho-






Fig. 2.3.1 Validation of siRNA-mediated frataxin knockdown in fibroblasts derived from a healthy 
control individual.  Representative Western blot of healthy fibroblasts transfected with FXN-
targeted siRNA or a non-targeting siRNA control (A).  FXN levels were decreased to 36% of 





Fig. 2.3.2 Frataxin knockdown does not significantly alter Drp1 or (S616) phospho-Drp1 protein 
levels.  Representative Western blot healthy fibroblasts transfected with FXN-targeted siRNA or a 
non-targeting siRNA control (A).  FXN knockdown did not significantly alter the overall levels of 












Fig. 2.3.3 Frataxin knockdown significantly increases the level of Mcl1.  Representative Western 
blot of healthy fibroblasts transfected with FXN-targeted siRNA or a non-targeting siRNA control 
(A).  FXN was decreased to 20% of control, and Mcl1 were increased to 390% of control (B).  










Fig. 2.3.4 FXN knockdown significantly increases the percentage of cells with fragmented 
mitochondria.  ICC of a mitochondrial marker in healthy fibroblasts transfected with a non-
targeting siRNA (A) or FXN-targeted siRNA (B).  FXN knockdown increased the percentage of 






Fig. 2.3.5 Frataxin knockdown increases the number of mitochondrial fragments per cell.  ICC of 
a mitochondrial marker in healthy fibroblasts transfected with a non-targeting siRNA (A) or FXN-
targeted siRNA (B).  FXN knockdown increased the number of mitochondrial fragments per cell 







Fig. 2.3.6 Frataxin knockdown increases the number of (Ser616) phospho-Drp1 clusters per cell.  
ICC of (Ser616) phospho-Drp1 in healthy fibroblasts transfected with a non-targeting siRNA (A) or 
FXN-targeted siRNA (B).  FXN knockdown increased the number of (Ser616) phospho-Drp1 







Fig. 2.3.6 Frataxin knockdown does not alter ATP levels.  A luminescence-based assay to 
quantify the relative amount of ATP in cells reveals that FXN knockdown did not significantly alter 
ATP levels (A).  n. s. not significant, two-sided t-test. n=3. 
 
 
2.4 Patient-derived cells 
 The results of sub-acute FXN deficiency were then compared to those of chronic FXN 
deficiency.  Fibroblasts derived from 3 individual FRDA patients exhibited 0.17 times the level of 
FXN observed in fibroblasts derived from a healthy individual (Fig. 2.4.1).  The total levels of Drp1 
and (Ser616) phospho-Drp1 protein were unaffected (Fig. 2.4.2).  The levels of FXN RNA 
transcripts were significantly decreased and CDK1 transcripts were significantly increased, while 
the levels of Drp1 and Mcl1 transcripts were unchanged (Fig. 2.4.3).  A significantly higher 
percentage of FRDA patient fibroblasts exhibited fragmented mitochondria compared to healthy 
fibroblasts (Fig. 2.4.4).  The FRDA patient-derived fibroblasts exhibited significantly increased 
mitochondrial fragmentation (Fig. 2.4.5) and significantly increased (Ser616) phospho-Drp1 
clustering (Fig. 2.4.6) per cell.  These patient-derived fibroblasts exhibited significantly decreased 






Fig. 2.4.1 FRDA patient fibroblasts have lower levels of FXN than healthy controls.  
Representative Western blot of FRDA patient-derived fibroblasts (A).  FRDA patient-derived 
fibroblasts exhibited 17% the level of FXN in healthy control fibroblasts (B).  *p<0.05, Wilcoxon 






Fig. 2.4.2 FRDA patient fibroblasts do not have significantly altered levels of Drp1 or (Ser616) 
phospho-Drp1 protein.  Representative Western blot of FRDA patient-derived fibroblasts (A).  
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FRDA patient-derived fibroblasts did not exhibit significantly altered levels of (Ser616) phospho-




Fig. 2.4.3 Alterations to gene transcripts for proteins that regulate mitochondrial morphology.  
These data are derived from the normalized levels of mRNA transcripts.  FRDA patient cells 
exhibit significantly decreased FXN transcripts (43.7% of healthy controls, A).  Drp1 transcript 
levels were not significantly altered (B).  CDK1 transcript levels were significantly increased to 
364.4% the levels observed in healthy controls (C).  Mcl1 transcript levels were not significantly 






Fig. 2.4.4 A significantly higher proportion of FRDA patient-derived fibroblasts compared to 
healthy controls.  ICC of a mitochondrial marker in healthy control fibroblasts (A) or FRDA patient-
derived fibroblasts (B).  While 9.8% of healthy control fibroblasts exhibited fragmented 
mitochondria, 44.8% of FRDA patient-derived fibroblasts exhibited fragmented mitochondria (C).  








Fig. 2.4.5 FRDA patient fibroblasts have significantly increased mitochondrial fragments per cell 
compared to healthy controls.  ICC of a mitochondrial marker in healthy control fibroblasts (A) or 
FRDA patient-derived fibroblasts (B).  While controls exhibited 182 mitochondrial fragments per 
cell, FRDA patient-derived fibroblasts exhibit 580 fragments per cell (C).  *p<0.05, two-sided t-







Fig. 2.4.6 FRDA patient fibroblasts have significantly increased (Ser616) phospho-Drp1 clusters 
per cell compared to healthy controls.  ICC of (Ser616) phospho-Drp1 in healthy control 
fibroblasts (A) or FRDA patient-derived fibroblasts (B).  While controls exhibited 828 (Ser616) 
phospho-Drp1 clusters per cell, FRDA patient-derived fibroblasts exhibited1448 clusters per cell 







Fig. 2.4.7 FRDA patient fibroblasts have significantly decreased levels of ATP compared to 
healthy controls.  A luminescence-based assay to quantify the relative amount of ATP in cells 
reveals that FRDA patient-derived fibroblasts exhibited 90% the level of ATP in healthy controls 






2.5 Exogenous frataxin overexpression 
 To determine whether the effects of chronic FXN deficiency are reversible and directly 
dependent upon FXN expression, 3 FRDA patient-derived fibroblast lines were transfected with a 
plasmid encoding FXN.  This transfection resulted in FXN expression at 260% observed in FRDA 
patient fibroblasts transfected with an empty vector (Fig. 2.4.1).  FXN overexpression did not alter 
the total levels of Drp1 or (Ser616) phospho-Drp1 protein (Fig. 2.4.2), but it significantly 
decreased both mitochondrial fragmentation (Fig. 2.4.3) and (Ser616) phospho-Drp1 clustering 






Fig. 2.5.1 Validation of FXN transfection and overexpression.  Representative Western blot of 
FRDA patient-derived fibroblasts transfected with either an empty vector or a plasmid encoding 
human FXN (A).  Transfection increased FXN expression to 260% of the vector control (B).  








Fig. 2.5.2 Frataxin overexpression does not affect the levels of Drp1 or (Ser616) phospho-Drp1.  
Representative Western blot of FRDA patient-derived fibroblasts transfected with either an empty 
vector or a plasmid encoding human FXN (A).  FXN transfection does not significantly alter the 












Fig. 2.5.3 Frataxin overexpression decreases the number of mitochondrial fragments per cell in 
FRDA patient-derived fibroblasts.  ICC of a mitochondrial marker in FRDA patient-derived 
fibroblasts transfected with an empty vector (A) or a plasmid encoding FXN (B).  FXN transfection 
decreased the number of mitochondrial fragments per cell from 594 to 335 (C).  **p<0.01, two-






Fig. 2.5.4 Frataxin overexpression decreases the number of (Ser616) phospho-Drp1 clusters per 
cell in FRDA patient-derived fibroblasts.   ICC of a (Ser616) phospho-Drp1 in FRDA patient-
derived fibroblasts transfected with an empty vector (A) or a plasmid encoding FXN (B).  FXN 
transfection decreased the number of (Ser616) phospho-Drp1 clusters per cell from 2261 to 856 





Fig. 2.5.5 Frataxin overexpression does not affect the level of ATP in FRDA patient-derived 
fibroblasts.  A luminescence-based assay to quantify the relative amount of ATP in cells reveals 
that FXN transfection did not significantly alter ATP levels in FRDA patient-derived fibroblasts (A). 











Mitochondrial fragmentation is significantly increased within 72 hours of FXN knockdown 
in healthy fibroblasts, suggesting that this mechanism responds rapidly to FXN deficiency.  
Moreover, it reveals that fragmentation is a direct response to FXN deficiency, rather than a 
response to alterations in other pathways that may occur during chronic FXN deficiency.  While 
FXN knockdown does not alter the overall levels of (Ser616) phospho-Drp1 or Drp1, the number 
of (Ser616) phospho-Drp1 clusters is significantly increased.  It is possible that the rate of 
turnover for this protein is longer, so an extended time course may reveal differences in the 
overall levels of these proteins.  The initial response, however, appears dependent upon (Ser616) 
phospho-Drp1 oligomerization and localization to the mitochondria.  In addition to the increased 
number of (Ser616) phospho-Drp1 clusters, this idea is further supported by the increased levels 
of Mcl1, the protein that chaperones (Ser616) phospho-Drp1 to the mitochondria.  FXN 
knockdown, however, does not alter the level of ATP.  It is conceivable that fibroblasts are initially 
able to cope with FXN deficiency such that ATP levels remain unchanged.  Mitochondrial 
fragmentation, which increases the mitochondrial surface area, may represent an adaptive, 
homeostatic mechanism in FRDA by which cells maintain ATP levels; further evidence for this 
hypothesis will be discussed in Chapter 3. 
The standard method for the field to quantify mitochondrial fragmentation involves a 
blinded individual counting the number of cells that appear to exhibit tubular or fragmented 
mitochondria.   Indeed, a significantly higher percentage of FRDA patient-derived fibroblasts 
exhibit fragmented mitochondria compared to healthy controls (Fig. 2.3.4 and 2.4.4).  The 
author’s novel method for quantifying mitochondrial fragmentation in a more quantitative and 
reproducible manner achieves similar results, with FRDA patient derived fibroblasts exhibiting an 
increased number of mitochondrial fragments per cell compared to healthy controls (Fig. 2.3.5 
and 2.4.5).  The parallel between these results validates this novel method as an effective and 
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reliable means to quantify mitochondrial fragmentation, and this method will be used throughout 
the succeeding chapters due to its increased rigor and reproducibility. 
GRP75 (Hsp70) immunostaining provided higher resolution images of the mitochondria 
than other mitochondrial markers (preliminary data, not shown).  This protein predominantly 
localizes to the mitochondria, making it a useful mitochondrial marker121-123.  However, some 
evidence suggests that a percentage of GRP75 also localizes to other sub-cellular 
compartments124.  Because it primarily localizes to the mitochondria, the immunofluorescence 
signal from mitochondrial GRP75 would be more intense than the signal from extramitochondrial 
copies of the protein; as such, the low immunofluorescence signaling resulting from 
extramitochondrial GRP75 was eliminated by setting a minimum signal threshold before 
quantifying the number of mitochondrial fragments per cell. 
 Chronic FXN deficiency as observed in FRDA patient-derived fibroblasts results in similar 
phenotypes to those exhibited during sub-acute FXN deficiency.  Mitochondrial fragmentation is 
increased while the levels of (Ser616) phospho-Drp1 and Drp1 are unaltered.  Additionally, Drp1 
transcript levels are unchanged in FRDA patient derived fibroblasts while CDK1 transcript levels 
are significantly increased.  Since CDK1 phosphorylates Drp1 at Ser616, this may represent a 
potential mechanism by which Drp1 is activated in FRDA.  As Mcl1 chaperones (Ser616) 
phospho-Drp1 to the mitochondria, this protein may represent another mechanism by which 
mitochondrial fragmentation occurs in FRDA.  Mcl1 protein levels are increased in FXN 
knockdown fibroblasts; however, the transcript levels are unchanged in FRDA patient fibroblasts.  
This may represent a difference between sub-acute and chronic FRDA models; moreover, it is 
conceivable that Mcl1 levels and/or activity are altered post-transcriptionally.  Additionally, the 
level of ATP in FRDA patient-derived fibroblasts is significantly lower than in control fibroblasts, 
suggesting that these cells may initially be able to cope with FXN deficiency but become less 
capable of doing so in a chronic state. 
 Exogenous FXN expression in FRDA patient-derived fibroblasts largely rescues the 
abnormal mitochondrial phenotypes they express; the number of mitochondrial fragments and 
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(Ser616) phospho-Drp1 clusters per cell are significantly decreased.  This provides further 
evidence that mitochondrial fragmentation in FRDA is directly dependent upon FXN expression 
levels.  However, FXN expression does not restore ATP levels in these patient-derived 
fibroblasts.  It is possible that these cells utilize FXN-independent pathways to generate ATP.  
While such an approach is not quite as effective as FXN-dependent pathways, as demonstrated 
by the significantly lower ATP levels in patient cells, increased utilization of such pathways may 
represent a mechanism by which the cells adapt to FXN deficiency.  As the cells rely less upon 
FXN-dependent pathways, re-expression of FXN does not alter ATP levels.  It is possible that 
FXN transfection over a longer time course may cause the cells to revert to FXN-dependent 
mechanisms for ATP synthesis, resulting in increased ATP levels; alternatively, the chronic FXN 
deficiency may drive the cells into a relatively irreversible state of FXN-independent ATP 
synthesis such that FXN expression may not improve cellular bioenergetics regardless of the time 
course.   
The lack of increased ATP synthesis in FRDA patient-derived cells with FXN transfection 
has critical implications for gene therapy approaches to treating FRDA.  A current investigation 
includes administering a FXN-encoding plasmid to the KIKO model through intravenous and/or 
intracerebroventricular injections.  Even if such an approach restores FXN levels in critical tissues 
like the cerebellum, however, it remains unproven whether FXN expression in FRDA patients will 
provide any benefit.  Moreover, the level of FXN protein re-expression resulting from such gene 
therapy may impact the cellular and organismal responses.  Further investigation of the potential 
benefits, or lack thereof, of FXN re-expression in FRDA models should be conducted before 




CHAPTER 3- EFFECTS OF TAT-P110 ON MITOCHONDRIAL MORPHOLOGY AND CELL 
VIABILITY IN FRIEDREICH ATAXIA MODELS 
 
3.1 Abstract 
 The GTPase Drp1 execute mitochondrial fragmentation; when phosphorylated at its 
(Ser616) residue, Drp1 is recruited to MAM’s by Mcl1, oligomerizes into clusters, and 
mechanically severs the mitochondria.  To determine whether mitochondrial fragmentation in 
FRDA is dependent upon Drp1 activity, sub-acute and chronic models of FRDA were treated with 
a Drp1 inhibitor, and the relevant outcome measures were quantified similarly to Chapter 2. 
P110 is small peptide that inhibits (Ser616) phospho-Drp1 from binding to the 
mitochondria.  In several neurodegenerative and cardiomyopathy disease models, treatment with 
this peptide reverses mitochondrial fragmentation and improves cellular bioenergetics71-73,75,76.  
To improve cellular uptake, a cell-penetrating TAT domain may be added to the N-terminus of 
P11072.  The effects of this drug on sub-acute and chronic FRDA models have not previously 
been studied. 
The goal of this chapter is to determine whether mitochondrial fragmentation in FRDA is 
dependent upon Drp1 activity.  Moreover, this chapter will explore whether mitochondrial 
fragmentation represents a beneficial, homeostatic mechanism or a maladaptive mechanism in 
FRDA.  This chapter will begin to investigate the pathway by which FXN deficiency may cause 
mitochondrial fragmentation and will explore whether mitochondrial fragmentation represents a 
viable therapeutic target in FRDA. 
  
3.2 Introduction 
 Chapter 2 established that FXN deficiency causes excessive mitochondrial fragmentation 
in FRDA, likely through increasing (Ser616) phospho-Drp1 localization to the mitochondria by 
upregulating the chaperone protein Mcl1.  While it establishes a correlation between increased 
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(Ser616) phospho-Drp1 clustering and increased mitochondrial fragmentation in FRDA, the data 
in Chapter 2 do not establish a causative link between these observations.  The goal of Chapter 3 
is to determine whether mitochondrial fragmentation in FRDA is dependent upon Drp1 activity. 
 Drp1 inhibition in sub-acute and chronic FRDA models provides a valuable tool for 
elucidating this pathway.  The small peptide mdivi-1 had previously been widely utilized as a 
mitochondrial fission inhibitor; however, although this peptide inhibits the GTPase activity of Drp1, 
it also inhibits Bax-mediated permeabilization of the OMM, thereby preventing cytochrome c 
release125.  While mdivi-1 is more selective than a previous inhibitor of mitochondrial 
fragmentation126, a Drp1 inhibitor that is more selective than mdivi-1 has since replaced this drug 
in pathway analysis experiments.  P110 selectively inhibits the GTPase activity of Drp1 and 
prevents Drp1 from binding to Fis1, thus preventing Drp1 from binding to and severing the 
mitochondria70.  To investigate the pathway by which FXN deficiency cause mitochondrial 
fragmentation in FA, P110 serves as a valuable tool due to its high selectivity for Drp1. 
 Furthermore, P110, sometimes fused to the cell-penetrating TAT sequence on its N-
terminus, provides bioenergetic benefits in several neurodegenerative disease models71-74.  This 
drug may increase ATP synthesis as well as ameliorate ROS accumulation in these models.  To 
determine whether TAT-P110 could likewise provide these benefits in FRDA, sub-acute and 
chronic models of FRDA were treated with this drug.  Following treatment, the levels of relevant 
proteins, ATP levels, the amount of mitochondrial fragmentation, and the number of (Ser616) 
phospho-Drp1 clusters were quantified.  These experiments may thus provide insight as to 
whether mitochondrial fragmentation in FRDA is dependent upon Drp1 activity and whether 
mitochondrial fragmentation represents a homeostatic or a maladaptive mechanism in this 
disease. 
 
3.3 Frataxin knockdown with TAT-P110 
 To determine the effects of Drp1 inhibition on sub-acute FXN deficiency, healthy control 
fibroblasts were transfected with FXN-targeted siRNA and treated with 1 µM TAT-P110 for 72 
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hours.  TAT-P110 did not alter the level of FXN in healthy fibroblasts transfected with siRNA 
targeting FXN (Fig. 3.3.1).  This drug significantly decreased the number of mitochondrial 
fragments (Fig. 3.3.2) as well as (Ser616) phospho-Drp1 clusters (Fig. 3.3.3) in these FXN 
knockdown cells.  The overall levels of Drp1 and (Ser616) phospho-Drp1, however, were 
unaffected (Fig. 3.3.4).  Preventing mitochondrial fragmentation in FXN knockdown fibroblasts 





Fig. 3.3.1. TAT-P110 does not alter the level of FXN in healthy fibroblasts transfected with FXN-
targeted siRNA.  Representative Western blot of healthy fibroblasts transfected with FXN-
targeted siRNA and treated with 1 µM TAT-P110 or an inactive control peptide (Scrambled TAT-
P110) for 72 hours (A).  The Drp1 inhibitor did not alter the level of FXN (B).  n.s. not significant, 






Fig. 3.3.2 TAT-P110 does not alter the overall levels of Drp1 or (Ser616) phospho-Drp1 in healthy 
fibroblasts transfected with FXN-targeted siRNA.  Representative Western blot of healthy 
fibroblasts transfected with FXN-targeted siRNA and treated with 1 µM TAT-P110 or an inactive 
control peptide (Scrambled TAT-P110) for 72 hours (A).  The Drp1 inhibitor did not alter the levels 









Fig. 3.3.3 TAT-P110 significantly decreases the number of mitochondrial fragments per cell 
resulting from FXN knockdown in healthy fibroblasts.  ICC for a mitochondrial marker in FXN-
knockdown fibroblasts treated with 1 µM of an inactive control peptide (scrambled TAT-P110, A) 
or TAT-P110 (B) for 72 hours.  The Drp1 inhibitor significantly decreased the number of 








Fig. 3.3.4 TAT-P110 significantly decreases the number of (Ser616) phospho-Drp1 clusters per 
cell resulting from FXN knockdown in healthy fibroblasts.  ICC for (Ser616) phospho-Drp1 in 
FXN-knockdown fibroblasts treated with 1 µM of an inactive control peptide (scrambled TAT-
P110, A) or TAT-P110 (B) for 72 hours.  The Drp1 inhibitor significantly decreased the number of 







Fig. 3.3.5 TAT-P110 significantly decreases the level of ATP in FXN knockdown fibroblasts.  A 
luminescence-based assay performed on FXN knockdown fibroblasts reveals that TAT-P110 





3.4 Patient-derived cells with TAT-P110 
  
 To investigate the effects of Drp1 inhibition on chronic FXN deficiency, 2 FRDA patient-
derived fibroblast cell lines were treated with 1 µM of an inactive control peptide (scrambled TAT-
P110) or TAT-P110 for 72 hours.  At this time course and concentration, TAT-P110 did not 
significantly impact the levels of FXN, Drp1, or (Ser616) phospho-Drp1 in FRDA patient-derived 
fibroblasts (Fig. 3.4.1 and Fig. 3.4.2).  TAT-P110 treatment resulted in an insignificant trend 
toward decreasing the number of mitochondrial fragments per cell (Fig. 3.4.3), and significantly 
decreased the number of (Ser616) phospho-Drp1 clusters per cell (Fig. 3.4.4).  Moreover, TAT-
P110 treatment resulted in an insignificant trend toward decreasing the ATP levels in FRDA-







Fig. 3.4.1 TAT-P110 does not alter the level of FXN in FRDA patient-derived fibroblasts.  
Representative Western blot of FRDA patient-derived fibroblasts treated with 1µM TAT-P110 or 
inactive control peptide (scrambled TAT-P110 for 72 hours (A).  The Drp1 inhibitor did not 









Fig. 3.4.2 TAT-P110 does not alter the overall levels of Drp1 or (Ser616) phospho-Drp1 in FRDA 
patient-derived fibroblasts.  Representative Western blot of FRDA patient-derived fibroblasts 
treated with 1µM TAT-P110 or inactive control peptide (scrambled TAT-P110 for 72 hours (A).  
The Drp1 inhibitor did not significantly alter the levels of (Ser616) phospho-Drp1 or Drp1 (B).  n.s. 







Fig. 3.4.3 TAT-P110 trends toward decreasing the number of mitochondrial fragments per cell in 
FRDA patient-derived fibroblasts.  ICC of a mitochondrial marker for FRDA patient-derived 
fibroblasts treated with an inactive control peptide (scrambled TAT-P110, A) or 1µM TAT-P110 
(B) for 72 hours.  The Drp1 inhibitor did not significantly alter the number of mitochondrial 
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Fig. 3.4.4 TAT-P110 significantly decreases the number of (Ser616) phospho-Drp1 clusters per 
cell in FRDA patient-derived fibroblasts.  ICC of (Ser616) phospho-Drp1 for FRDA patient-derived 
fibroblasts treated with an inactive control peptide (scrambled TAT-P110, A) or 1µM TAT-P110 
(B) for 72 hours.  The Drp1 inhibitor significantly decreased the number of (Ser616) phosho-Drp1 
clusters per cell from 3476 to 2095 (C).  *p<0.05, two-sided t-test. n=3 technical replicates for 







Fig. 3.4.5 TAT-P110 trends toward decreasing ATP levels in FRDA patient-derived fibroblasts.  A 
luminescence-based assay performed on FXN knockdown fibroblasts reveals that TAT-P110 did 
not significantly alter ATP levels in FRDA patient-derived fibroblasts (A).  n. s. not significant, 




 Treatment with 500 nM to 1 µM of P110 appears to provide the maximal benefits in other 
disease models71-74, so the FRDA models were treated with 1 µM of this drug; in the FXN 
knockdown model, drug treatment occurred simultaneously with siRNA transfection.  The 72-hour 
time course was selected because at this time point following siRNA transfection, the levels of 
FXN in the knockdown model are approximately equivalent to the FXN levels in the FRDA 
patient-derived fibroblasts.  This allows for a reasonable comparison between the two models to 
parse the differences between the cellular response to TAT-P110 at the sub-acute and chronic 
stages of FXN deficiency. 
TAT-P110 does not alter the levels of FXN, (Ser616) phospho-Drp1, or Drp1 in FXN 
knockdown fibroblasts.  As this drug inhibits the GTPase activity of Drp1 and prevents it from 
binding to the mitochondria, it is unsurprising that the level of Drp1 is unaffected within 72 hours 
of treatment.  The number of (Ser616) phospho-Drp1 clusters is significantly decreased, which is 
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indicative of the drug’s mechanism of action.  TAT-P110 significantly decreases the number of 
mitochondrial fragments per cell; this drug specifically inhibits Drp1 activity, suggesting that FXN-
deficiency-induced mitochondrial fragmentation is dependent upon Drp1 activity.  In neither the 
sub-acute nor the chronic model does Drp1 inhibition alter the level of FXN, suggesting that 
mitochondrial fragmentation is a downstream event of FXN deficiency; while restoring FXN levels 
reverses mitochondrial fragmentation (see Chapter 2), reversing mitochondrial fragmentation 
does not restore FXN levels. 
TAT-P110 significantly decreases the level of ATP in FXN-knockdown fibroblast.  
Because this Drp1 inhibitor both prevents mitochondrial fragmentation and decreases ATP levels, 
mitochondrial fragmentation appears to be an adaptive, homeostatic mechanism in FRDA that 
allows cells to initially cope with FXN deficiency.  Compare this result to the effects of P110 in 
other neurodegenerative diseases; in models of AD, PD, MS, and HD, Drp1 inhibition both 
reversed mitochondrial fragmentation and improved cellular respiration71-74,127.  In these diseases, 
mitochondrial dysfunction appears to be a secondary feature of the disease, far downstream of 
the factor that causes the disease.  Mitochondrial fragmentation in these diseases, then, appears 
to be a maladaptive mechanism, and as such, reversing fragmentation may prove beneficial for 
the cell.  Contrarily, mitochondrial dysfunction is a primary feature of FRDA, a direct consequence 
of FXN deficiency.  This suggests that mitochondrial fragmentation is an adaptive mechanism in 
FRDA that allows the cells to maintain ATP synthesis initially after the insult of FXN deficiency.  
Therefore, unlike several other neurodegenerative disease, mitochondrial fragmentation does not 
appear to be a viable therapeutic target for FRDA. 
In FRDA patient-derived fibroblasts, TAT-P110 is less effective than in FXN-knockdown 
fibroblasts.  The Drp1 inhibitor still significantly decreases the number of (Ser616) phospho-Drp1 
clusters, which is indicative of the drugs activity, but it only trends toward decreasing the number 
of mitochondrial fragments per cell; similarly, this drug trends toward decreasing the cellular 
levels of ATP.  First, these results are indicative of the inherent differences between sub-acute 
and chronic models of disease: cells remain malleable for some time after an initial insult, but as 
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the cells enter a chronic stage of disease, other adaptations are strongly expressed such that 
they are less capable of being altered.  It is possible that the cells require a longer time course to 
exhibit further changes.  Second, both the number of mitochondrial fragments per cell and the 
cellular level of ATP trend toward a decrease in FRDA patient fibroblasts.  This suggests that a 
correlation may exist between the amount of mitochondrial fragmentation and the cell’s ability to 
generate ATP, further suggesting that mitochondrial fragmentation is a homeostatic mechanism, 





CHAPTER 4- EFFECTS OF SS-31 ON MITOCHONDRIAL MORPHOLOGY AND CELL 
VIABILITY IN FRIDREICH ATAXIA MODELS 
 
4.1 Abstract 
 SS-31 is a small peptide that stabilizes cardiolipin (CL), a four-tailed phospholipid critical 
for cristae formation on the IMM and for anchoring the ETC complexes77.  Oxidation of CL results 
in cytochrome c release and impaired ETC function, leading to decreased ATP synthesis.  SS-31 
is thought to stabilize the electrostatic interactions between CL and these various IMM proteins as 
well as inhibit CL oxidation.  This peptide reverses mitochondrial fragmentation and improves 
bioenergetics, in several neurodegenerative disease models82,84,85,128.  Additionally, this peptide 
reverses mitochondrial fragmentation in one FRDA patient-derived lymphoblast cell line87.  
However, as individual patients or tissue types may respond differently to a given drug, it is 
necessary to study the effects of SS-31 on cell lines derived from multiple patients and from 
different tissue types.  Additionally, the effects of SS-31 on an in vivo model of FRDA have not 
previously been investigated. 
 The goal of this chapter is to identify the effects of SS-31 on FXN and Drp1 protein levels 
in vivo.  Additionally, this chapter explores the effects of SS-31 on up to 5 FRDA patient-derived 
fibroblasts lines, offering a more comprehensive study of this peptide’s effects to account for 
variability across individuals.  The effects of SS-31 on mitochondrial fragmentation, protein levels, 
and ATP levels are investigated.  Furthermore, a comparison between SS-31 and TAT-P110 is 
performed.  FRDA patient-derived fibroblasts are treated with both drugs simultaneously to 
determine whether the effects of the drugs are additive.  This provides insight into the 
mechanisms of action of these drugs, suggesting that they exert their effects at different points 







 Cardiolipin is a four-tailed fatty acid derivative of phosphatidic acid78.  The unusual four-
tailed structure of CL allows this phospholipid to play a critical role in maintaining membrane 
morphology81.  While CL primarily localizes to the inner mitochondrial membrane (IMM), this 
phospholipid may also localize to the outer mitochondrial membrane (OMM) where it contributes 
to regulating mitochondrial dynamics78,81,129,130.  Due to its unique four-tailed structure, CL is 
critical for cristae formation on the IMM78,81.  Additionally, CL anchors the electron transport chain 
(ETC) complexes to the IMM and brings these complexes in close proximity to one another, 
optimizing ETC functioning78.  Moreover, electrostatic interactions between CL and cytochrome c 
inhibit cytochrome c release from the mitochondria, thereby preventing this apoptosis signaling 
mechanism80,131.  However, when these electrostatic interactions are disrupted (e.g. through 
cellular accumulation of ROS), cytochrome c is released from the mitochondria, resulting in 
apoptosis signaling79,80,131.  Due to these critical functions in bioenergetics, mitochondrial 
dynamics, and apoptosis, CL deficiency has severe pathophysiological implications.  For 
instance, Barth syndrome results from a mutation in the tafazzin gene which encodes a 
transacylase that facilitates CL remodeling during its conversion from phosphatidic acid132,133.  
Certain features of Barth syndrome, including mitochondrial dysfunction, cardiomyopathy, and 
increased susceptibility to fatigue, parallel features of FRDA132-134.  The parallels between the CL-
deficiency disease Barth syndrome and FRDA provide a rationale for studying the role of CL in 
FRDA.  Therefore, it is reasonable to investigate the potential therapeutic benefits of targeting CL 
in FRDA. 
 Szeto-Schiller compound 31 (SS-31) targets CL, potentially protecting the electrostatic 
interactions between CL and other mitochondrial proteins from disruption by ROS77.  The 
therapeutic effects of this compound have been investigated in several neurodegenerative and 
cardiomyopathy disease models, including a study in one FRDA lymphoblast cell line82-85,87,128,135.  
SS-31 improves bioenergetics, ameliorates the effects of oxidative damage, and reverses 
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mitochondrial fragmentation in numerous disease models82-85,87,128,135.  SS-31 reverses 
mitochondrial fragmentation and increases FXN levels in one FRDA patient-derived lymphoblast 
line87. 
 While in vitro diseases models, like the sub-acute and chronic fibroblast models of FRDA 
provide valuable tools for pathway analysis and drug mechanism of action studies, such models 
have limitations.  Cell cultures do not accurately represent the organismal environment.  
Interactions across tissue types may alter the cellular response to drugs, and in vitro results do 
not necessarily transfer directly to in vivo models or to humans.  In vivo experiments, while still 
not fully reflective of humans, may supplement in vitro data by offering a comparison between 
cellular and organismal level data.  Therefore, Chapter 4 employs both in vitro and in vivo models 
to examine the effects of SS-31.  The Knock-in/Knockout (KIKO) mouse model of FRDA (Jackson 
Laboratories #012329 B6.Cg-Fxn(tm1.1Pand) Fxn(tm1Mkn/J)) contains a null mutation on one 
FXN allele and a humanized expansion sequence on the second FXN allele .  In addition to FXN 
deficiency, this mouse also presents certain molecular and neurobehavioral features that reflect 
FRDA patients113-115.  The Knock-in/Wild type mouse (KIWT) serves as control; this mouse has 
one wild type FXN allele and a humanized expansion sequence in the second FXN allele.  While 
still limited by the inherent differences between mice and humans, these models provide valuable 
data that supplement in vitro results. 
 The goal of this chapter is to investigate the effects of SS-31 in both in vivo and in vitro 
models of FRDA.  First, the effects of SS-31 on FXN levels in the KIWT and KIKO cerebellum are 
investigated.  Then, the effects of SS-31 on protein levels, mitochondrial fragmentation, (Ser616) 
phospho-Drp1 clustering, and ATP levels are investigated in the sub-acute and chronic fibroblast 
in vitro FRDA models.  These data provide information regarding the therapeutic potential for SS-
31 in FRDA and provides further insight into the mechanism of action of SS-31.  
 
4.3 Murine model with SS-31 
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 To determine the in vivo effects of SS-31 on protein levels, KIWT and KIKO mice were 
subcutaneously injected with SS-31 at 5mg/kg bodyweight. KIWT mice injected with SS-31 
exhibit significantly increased levels of FXN in the cerebellum by 256% (Fig. 4.2.1); contrarily, the 
levels of FXN were unaltered in the cerebella of KIKO mice were unaltered by SS-31 treatment 
(Fig.4.2.2)  In KIWT cerebellum, this drug significantly increased the levels of Drp1 and (Ser616) 
phospho-Drp1 by 148% and 149% respectively, although the ratio between the phosphorylated 
form and total level of Drp1 remained unchanged (Fig. 4.2.2).  In KIKO cerebellum, the levels of 
Drp1 and (Ser616) phospho-Drp1 were unchanged, although SS-31 resulted in a non-significant 




Fig. 4.3.1 SS-31 increases the level of FXN in KIWT cerebellum.  Representative Western blot of 
cerebellum from KIWT mice treated with SS-31 or vehicle control (A).  SS-31 increased FXN 








Fig. 4.3.2 SS-31 does not alter the level of FXN in KIKO cerebellum.  Representative Western 
blot of cerebellum from KIKO mice treated with SS-31 or vehicle control (A).  SS-31 did not 










Fig. 4.3.3 SS-31 increases the levels of Drp1 and (Ser616) phospho-Drp1 in KIWT cerebellum 
but does not alter the ratio between these two levels.  Representative Western blot of cerebellum 
from KIWT mice treated with SS-31 or vehicle control (A).  SS-31 increased the level of (Ser616) 
phospho-Drp1 by 148% (B) and increased the level of Drp1 by 149% (C).  The ratio between the 
level of (Ser616) phospho-Drp1 and Drp1 was unaffected by SS-31 (D).  n. s. not significant, 









Fig. 4.3.4 SS-31 does not alter the levels of or ratio between Drp1 and (Ser616) phospho-Drp1 in 
KIKO cerebellum.  Representative Western blot of cerebellum from KIKO mice treated with SS-31 
or vehicle control (A).  SS-31 did not significantly alter the levels of (Ser616) phospho-Drp1 (A), 
Drp1 (B), or the ratio between the levels of (Ser616) phospho-Drp1 and Drp1 (C).  n. s. not 




4.4 Patient-derived cells with SS-31 
 To determine the effects of SS-31 on a model of chronic FXN deficiency, 2 FRDA patient-
derived fibroblast cell lines were treated with 1 µM SS-31 for 72 hours.  SS-31 treatment 
significantly decreased the level of FXN in FRDA patient-derived fibroblasts to 42% of the levels 
in vehicle-treated controls (Fig. 4.3.1), although it did not affect the overall levels of (Ser616) 
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phospho-Drp1 or Drp1 (Fig. 4.3.2).  This drug significantly decreased the number of mitochondrial 
fragments per cell (419 to 150 fragments per cell, Fig. 4.3.3) as well as the number of (Ser616) 
phospho-Drp1 clusters per cell (892 to 479 clusters per cell, Fig. 4.3.4).  The ATP levels in FRDA 
patient-derived fibroblasts were unaltered by SS-31 treatment (Fig. 4.3.5). 
 
 
Fig. 4.4.1 SS-31 significantly decreased the level of FXN in FRDA patient-derived fibroblasts.  
Representative Western blot of FRDA patient-derived fibroblasts treated with SS-31 (A).  This 
drug significantly decreased FXN levels to 42% of control levels (B).  *p>0.05, Wilcoxon sum-rank 






Fig. 4.4.2 SS-31 does not alter the levels of Drp1 or (Ser616) phospho-Drp1 in FRDA patient-
derived fibroblasts.  Representative Western blot of FRDA patient-derived fibroblasts treated with 
SS-31 (A).  This drug did not significantly alter the levels of (Ser616) phospho-Drp1 or Drp1 (B). 





Fig. 4.4.3 SS-31 significantly decreases the number of mitochondrial fragments per cell in FRDA 
patient-derived fibroblasts.  ICC for a mitochondrial marker in FRDA patient-derived fibroblasts 
treated with a vehicle control (A) or with SS-31 (B).  This drug decreased the number of 
mitochondrial fragments per cell from 419 to 150 (C).  ***p<0.001, two-sided t-test. n=4 technical 







Fig. 4.4.4 SS-31 significantly decreases the number of (Ser616) phospho-Drp1 clusters per cell in 
FRDA patient-derived fibroblasts.  ICC for (Ser616) phospho-Drp1 in FRDA patient-derived 
fibroblasts treated with a vehicle control (A) or SS-31 (B).  SS-31 decreased the number of 
(Ser616) phospho-Drp1 clusters per cell from 892 to 479 (C).  *p<0.05, two-sided t-test. n=4 






Fig. 4.4.5 SS-31 does not alter the level of ATP in FRDA patient-derived fibroblasts.  
Luminescence-based assay for quantifying the relative amount of ATP in cells revealed that SS-
31 does not significantly alter ATP levels (A).  n. s. not significant, two-sided t-test. n=2 technical 
replicates for each of 5 biological replicates. 
 
 
4.5 Combination of TAT-P110 and SS-31 in patient-derived cells 
 To determine whether TAT-P100 and SS-31 act on the same pathway, 3 FRDA patient-
derived fibroblast cell lines were treated with a combination of 1 µM TAT-P110 and 1 µM SS-31 
for 72 hours.  This drug combination did not alter the levels of FXN, Drp1, of (Ser616) phospho-
Drp1 differently from SS-31 alone (Fig. 4.4.1 and Fig. 4.4.2).  Similarly, the number of 
mitochondrial fragments and the number of (Ser616) phospho-Drp1 clusters were unchanged 
when comparing the combination treatment to treatment with SS-31 alone (Fig. 4.4.3 and Fig. 
4.4.4).  The ATP levels in FRDA patient-derived cells treated with the drug combination trended 





Fig. 4.5.1 The combination of TAT-P110 and SS-31 does not alter the level of FXN in FRDA 
patient-derived fibroblasts compared with SS-31 alone.  Representative Western blot of FRDA 
patient-derived fibroblasts treated with a combination of TAT-P110 and SS-31 (A).  The drug 
combination did not alter FXN levels differently from treatment with SS-31 alone (B).  n. s. not 







Fig. 4.5.2 The combination of TAT-P110 and SS-31 does not alter the overall levels of Drp1 or 
(Ser616) phospho-Drp1 in FRDA patient-derived fibroblasts compared with SS-31 alone.  
Representative Western blot of FRDA patient-derived fibroblasts treated with a combination of 
TAT-P110 and SS-31 (A).  The drug combination did not alter (Ser616) phospho-Drp1 or Drp1 
levels differently from treatment with SS-31 alone (B).  n. s. not significant, Wilcoxon sum-rank 








Fig. 4.5.3 The combination of TAT-P110 and SS-31 does not alter the number of mitochondrial 
fragments per FRDA patient-derived fibroblast compared to SS-31 alone.  ICC for a mitochondrial 
marker in FRDA patient-derived fibroblasts treated with SS-31 alone (A) or with a combination of 
TAT-P110 and SS-31 (B).  The drug combination did not significantly change the number of 
mitochondrial fragments per cell compared to treatment with SS-31 alone (B).  n. s. not 







Fig. 4.5.4 The combination of TAT-P110 and SS-31 does not alter the number of (Ser616) 
phospho-Drp1 clusters per FRDA patient-derived fibroblast compared with SS-31 alone.  ICC for 
(Ser616) phospho-Drp1 in FRDA patient-derived fibroblasts treated with SS-31 alone (A) or with a 
combination of TAT-P110 and SS-31 (B).  The drug combination did not significantly change the 
number of (Ser616) phospho-Drp1 clusters per cell compared to treatment with SS-31 alone (B).  






Fig. 4.5.5 The combination of TAT-P110 and SS-31 trends toward decreasing the number of 
(Ser616) phospho-Drp1 clusters per FRDA patient-derived fibroblast compared with SS-31 alone.  
Luminescence-based assay reveals that a combination of TAT-P110 and SS-31 did not alter ATP 
levels compared to treatment with SS-31 alone (A).  n. s. not significant, two-sided t-test. n=2 





 The pathophysiological hallmarks of FRDA, including dysmetria and dysarthria, likely 
stem from abnormalities in the cerebellum, particularly the dentate nucleus136,137; improving 
cerebellar functioning would thus likely prove beneficial for FRDA patients.  While SS-31 
increased FXN levels in KIWT cerebellum, FXN was unaffected in KIKO cerebellum.  Perhaps 
SS-31 slows the rate of FXN turnover in KIWT but is incapable of achieving this effect in KIKO.  
Another possibility includes SS-31 indirectly affecting FXN transcription; since FXN may be 
silenced through methylation in FRDA patients30, the effects of SS-31 on protein levels may differ 
in KIWT and KIKO because of their different methylation patterns.  Further investigation is 
necessary to explore those potential hypotheses.   
This expression pattern (i.e. increasing FXN in control models while leaving FXN levels 
unaffected in FRDA models) is typical of other pre-clinical drug trials in FRDA models 
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(unpublished data).  These results therefore suggest that a multi-drug approach to FRDA may 
prove a more effective therapeutic strategy than utilizing a single-target drug. 
 SS-31 decreases the level of FXN in FRDA patient-derived fibroblasts, but another group 
reports that SS-31 increases FXN levels in FRDA patient lymphoblasts87.  This group treated the 
lymphoblasts for a 24-hour time course; it is possible that SS-31 results in a transient increase in 
FXN levels that reverses by 72 hours of treatment.  Additionally, the differences in these results 
may reflect tissue-specific effects of SS-31.  Finally, this group utilized a cell line from one FRDA 
patient while the experiments shown here utilize cell lines derived from 2-5 FRDA patients.  
Variability exists between individuals (e.g. age, sex), and this variability is further compounded in 
FRDA (e.g. GAA repeat length, age of disease onset).  The difference between these results may 
reflect differential responses between individual patients.  Utilizing cell lines from multiple FRDA 
patients and correlating the results with disease factors, particularly GAA repeat length, is critical 
for data interpretation.  The mitochondrial fragmentation and (Ser616) phospho-Drp1 cluster 
analyses presented in this dissertation use 2-3 biological replicates; while the results demonstrate 
that these features affect multiple individuals, the limited number of biological replicates has 
insufficient power to provide correlative data between GAA repeat length and the number of 
mitochondrial fragments and/or (Ser616) phospho-Drp1 clusters.  Future experiments seeking to 
draw such correlative conclusions should utilize an increased number of biological replicates.  
 In FRDA patient-derived fibroblasts, SS-31 significantly decreases the number of 
mitochondrial fragments per cell as well as the number of (Ser616) phospho-Drp1 clusters per 
cell.  This effect may in part be attributed to SS-31 stabilizing CL, since this phospholipid plays a 
critical role in maintaining the mitochondrial structure81.  Additionally, the action of SS-31 may 
potentiate CL’s roles in anchoring the ETC to the IMM and in bringing the ETC complexes within 
close proximity to one another, thereby improving cellular respiration82,83.  This improvement to 
bioenergetics may activate mitochondrial fusion, as fragmentation may no longer be necessary to 
maintain ATP homeostasis in FRDA patient cells treated with SS-31.  Despite reversing 
fragmentation, ATP levels are maintained during SS-31 treatment; contrast this to TAT-P110 
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treatment in which fragmentation is reversed, but ATP levels are decreased.  While SS-31 and 
TAT-P110 may both act on a pathway that contributes to mitochondrial fragmentation, the 
difference in these ATP level results suggests that these drugs have different targets.  Any loss in 
ATP synthesis from reversing fragmentation in SS-31-treated cells may be counteracted by 
increased ATP synthesis resulting from improvements to ETC function.  Therefore, if a potential 
therapeutic approach to FRDA reverses fragmentation, it must simultaneously improve another 
aspect of bioenergetics in order to be viable. 
 To further define the ability of SS-31 to ameliorate metabolic deficiencies in FRDA 
through protecting lipids against oxidative damage, a future experiment may include the use of 
BODIPY 581/591 C11 (Invitrogen D3861).  This fluorescent dye detects ROS in cell culture; upon 
oxidation of the polyunsaturated butadienyl portion of the dye, the fluorescence emission peak 
shifts in wavelength.  BODIPY 581/591 C11 may then detect whether SS-31 decreases ROS 
accumulation, thereby decreasing oxidative damage, in primary FRDA cell culture. 
 Since an optimal therapeutic strategy for FRDA will likely involve targeting multiple 
pathways, analyzing the direct targets of drugs and the pathways they affect is critical for rational 
drug design.  The combination of TAT-P110 and SS-31 does not affect FRDA patient-derived 
fibroblasts differently from SS-31 alone.  The trending decrease in ATP levels mirrors the effect of 
treating FRDA patient-derived fibroblasts TAT-P110 individually and can therefore be attributed to 
this drug.  The lack of differences between the drug combination and SS-31 alone suggests that 
these drugs act on the same pathway; if they act on different pathways, the two drugs would likely 
work synergistically, resulting in increased effects compared to either drug individually.  As such, 
this drug combination would likely be relatively ineffective in vivo.  A combination of SS-31, which 
improves bioenergetics in FRDA patient-derived cells, and a drug that acts on another pathway 





CHAPTER 5- CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1 Conclusions regarding TAT-P110 and SS-31 in Friedreich ataxia 
 
TAT-P110 and SS-31 both effectively inhibit mitochondrial fragmentation through 
decreasing Drp1 activity in sub-acute and chronic models of FRDA.  Both drugs result in 
decreased (Ser616) phospho-Drp1 clustering at the mitochondria; while TAT-P110 directly 
inhibits this Drp1 activity, it is a downstream effect of SS-31’s mechanism of action.  Treating cells 
with a combination of these two drugs does not result in different effects than treating with one 
drug, suggesting that the drugs affect the same enzymatic pathway.  However, they target 
different points along that pathway.  This becomes apparent when observing the effects of these 
drugs on ATP levels.  See Figure 5.1.1 for the putative pathway by which FXN deficiency causes 
mitochondrial fragmentation and the points at which TAT-P110 and SS-31 exert their effects. 
TAT-P110 selectively inhibits Drp1 activity, resulting in significantly decreased ATP levels 
in FXN-knockdown cells and a trend toward decreasing ATP in FRDA patient fibroblasts.  
Contrarily, SS-31 does not alter the ATP levels in FRDA patient fibroblasts, suggesting that SS-
31 acts upstream of Drp1 activity.  Indeed, SS-31 acts upon CL to improve ETC function and 
potentially to protect this phospholipid from oxidation.  Therefore, as FXN deficiency in FRDA 
impairs ETC functioning through decreased ISC biosynthesis, ETC dysfunction occurs prior to 
mitochondrial fragmentation in FRDA. 
While FXN transfection reverses mitochondrial fragmentation in FRDA patient fibroblasts, 
it does not increase ATP levels by the 72-hour time point.  It is possible that under chronic FXN 
deficiency, cells preferentially use the oxidative-phosphorylation pathway to generate ATP rather 
than glycolysis.  As the cells have switched ATP-synthesizing pathways, FXN re-expression may 
take longer than 72 hours to increase ATP levels as the cells switch back to utilizing glycolysis.  It 
is possible that other features of FRDA, like iron toxicity may also contribute to mitochondrial 
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fragmentation.  Perhaps FXN re-expression is capable of restoring such toxicity within the 72-
hour time point, resulting in fused mitochondria without restoring ATP levels.  Therefore, multiple 
pathologies, including ETC dysfunction, appear to present temporally before mitochondrial 
fragmentation in FRDA. 
 
Fig. 5.1.1 Potential pathway resulting in excessive mitochondrial fragmentation in FRDA.  FXN 
deficiency impairs ISC biosynthesis, which in turn impairs ETC function, decreasing ATP levels.  
In response, Drp1 is phosphorylated at (Ser616), is recruited to the mitochondria by Mcl1, and 
executes mitochondrial fragmentation.  At least sub-acutely, fragmentation is homeostatic 
mechanism that allows the cells to maintain ATP levels, although this mechanism fails as the 
cells enter a chronic state of FXN deficiency.  TAT-P110 inhibits Drp1 activity, thus preventing 
mitochondrial fragmentation and, in the sub-acute model, decreasing ATP levels.  SS-31 
improves ETC functioning, decreasing Drp1 activation, and reversing mitochondrial 
fragmentation.  While the improved ETC functioning would increase ATP levels, this effect may 
be counteracted by the loss of fragmentation as a homeostatic mechanism.  Through 
mechanisms not fully elucidated, ETC dysfunction may cause the cell to upregulate FXN 
expression, since improved ETC functioning results in decreased FXN levels (at the 72-hour 
timepoint in FRDA patient fibroblasts).  SS-31 and TAT-P110 thus operate at different points 







5.2 Preliminary results to guide future work on Nrf2 activators 
 
 One small molecule Nrf2 activator is RTA-408 (omaveloxelone).  This drug inhibits the 
interaction between Nrf2 and Keap1, improving bioenergetics in both in vitro and rodent models 
of FRDA138; furthermore, in phase I and phase II clinical trials, FRDA patients on RTA-408 
experienced a significant reversal in disease progression100.  To better understand the 
mechanism of action of this drug in FRDA, the effects of RTA-408 on mitochondrial dynamics, 
ATP levels, and FXN levels were studied. 
 To determine the effects of RTA-408 on mitochondrial fragmentation, healthy fibroblasts 
with FXN knockdown were treated with 100nM RTA-408 for 72 hours.  This drug significantly 
decreased the number of mitochondrial fragments per cell (Fig. 5.2.1) as well as the number of 
(Ser616) phospho-Drp1 clusters per cell (Fig. 5.2.2).  When applied to FRDA patient-derived 
fibroblasts, however, 100nM RTA-408 did not significantly alter the number of mitochondrial 
fragments (Fig. 5.2.3) or the number of (Ser616) phospho-Drp1 clusters (Fig. 5.2.4) per cell.  To 
further explore the pathway on which Nrf2 activators may exert their effects in FRDA patients, an 
RNA seq dataset was interrogated.  While FRDA patient fibroblasts have significantly decreased 
Nrf2 transcript levels, KEAP1 transcript levels are unchanged; however, Hrd1 transcript levels are 









Fig. 5.2.1 RTA-408 decreases the number of mitochondrial fragments in FXN-knockdown 
fibroblasts.  ICC for a mitochondrial marker in FXN-knockdown fibroblasts treated with vehicle (A) 
or 100nM RTA-408 (B).  This drug significantly decreased the number of mitochondrial fragments 









Fig. 5.2.2 RTA-408 decreases the number of (Ser616) phospho-Drp1 clusters per cell in FXN-
knockdown fibroblasts.  ICC for (Ser616) phospho-Drp1 in FXN-knockdown fibroblasts treated 
with vehicle (A) or 100nM RTA-408 (B).  This drug significantly decreased the number of (Ser616) 










Fig. 5.2.3 RTA-408 does not change the number of mitochondrial fragments per cell in FRDA 
patient fibroblasts.  ICC for a mitochondrial marker in FRDA patient-derived fibroblasts treated 
with vehicle (A) or 100nM RTA-408 (B).  This drug did not significantly alter the number of 
mitochondrial fragments per cell (C).  n. s. not significant, two-tailed t-test. n=3 technical 










Fig. 5.2.4 RTA-408 does not change the number of (Ser616) phospho-Drp1 clusters per cell in 
FRDA patient fibroblasts.  ICC for (Ser616) phospho-Drp1 in FRDA patient-derived fibroblasts 
treated with vehicle (A) or 100nM RTA-408 (B).  This drug did not significantly alter the number of 
(Ser616) phospho-Drp1 clusters per cell (C).  n. s. not significant, two-tailed t-test. n=3 biological 










Fig. 5.2.5 Nrf2 pathway gene transcript levels are altered in FRDA patient fibroblasts.  These data 
are derived from the normalized levels of mRNA transcripts.  FRDA patient cells exhibit 
significantly decreased Nrf2 transcripts (90% of healthy controls, A).  KEAP1 transcript levels 
were not significantly altered (B).  Hrd1 transcript levels are significantly increased to 130% the 










5.3 Conclusions regarding therapeutic approaches to Friedreich ataxia 
 
 FRDA cells exhibit excessive mitochondrial fragmentation that begins rapidly following 
FXN deficiency.  This mitochondrial fragmentation is a direct result of FXN deficiency and 
restoring FXN levels reverses fragmentation.  Additionally, fragmentation in FRDA is dependent 
upon Drp1 activity; FRDA cells exhibit increased clustering of (Ser616) phospho-Drp1 at the 
mitochondria.  This excessive Drp1-dependent mitochondrial fragmentation may be used as a 
biomarker disease, although it is not specific to FRDA.  Moreover, although excessive 
fragmentation is a feature of FRDA, it is not necessarily pathogenic; contrarily the data suggest 
that mitochondrial fragmentation is an adaptive mechanism in FRDA.  Inhibiting fragmentation 
decreases ATP level in the sub-acute model and trends toward decreasing ATP in the chronic 
model.  Therefore, while the amount of fragmentation may be utilized as a biomarker, reversing 
fragmentation should not serve as the sole rationale behind drug development for FRDA. 
 Rather, mitochondrial fragmentation may be used as one endpoint measure for drug 
effectiveness: a drug may exert its effect on a different target (e.g. the ETC), and as a 
consequence of the improved bioenergetics, the cell may reverse mitochondrial fragmentation.  
This appears to be the case with SS-31; this drug improves ETC function, and as a result, the cell 
may inhibit mitochondrial fragmentation (as well as potentially activating mitochondrial fusion).  In 
contrast, a drug like TAT-P110 that directly targets and inhibits mitochondrial fragmentation does 
not appear to be a viable therapeutic approach.  Directly inhibiting a homeostatic mechanism 
without improving some other cellular function is not a rational approach to drug design.  TAT-
P110 may be effective at improving bioenergetics for diseases in which fragmentation is a 
maladaptive mechanism; however, as fragmentation is homeostatic in FRDA, TAT-P110 alone 
would likely prove ineffective at improving bioenergetics. 
 While reversing fragmentation may not confer bioenergetics benefits to the cell, it may 
benefit the cell through other pathways.  The mitochondrial network interconnects with numerous 
other protein networks that are critical for protein synthesis and translocation139.  Excessive 
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mitochondrial fragmentation increases cellular susceptibility to apoptotic stimuli140.  Additionally, 
the fused mitochondrial network efficiently transports mitochondrial DNA (mtDNA) and is critical 
for mtDNA repair141.  Because accumulation of damaged mtDNA is a pathogenic feature of 
numerous diseases142, maintenance of a fused mitochondrial network may benefit the cell.  
Therefore, it is possible that reversing mitochondrial fragmentation in FRDA may be beneficial if a 
pharmacologic agent can simultaneously protect against the resultant decrease in ATP levels. 
 In addition to improving bioenergetics, increasing the levels of antioxidant response 
elements may be a viable therapeutic approach.  Nrf2 activators, such as RTA-408 and 
potentially LS-102, may represent viable drugs to improve the cell’s response to oxidant stress in 
FRDA100,103.  Even if oxidative damage is reduced, however, bioenergetics are likely to still be 
impaired.  Therefore, targeting both the antioxidant response element pathway (e.g. Nrf2 
activation) and a bioenergetics pathway (e.g. ETC stabilization) may present a more optimal 
therapeutic strategy than targeting any one pathway individually. 
 However, FRDA is a multi-tissue disease, and as such, it is very possible that different 
therapeutic strategies will be required for different tissues.  It will therefore be critical to 
investigate the effects of drugs in several tissue types and perhaps to increase drug delivery 
precision to specific cell types. 
While highly optimized therapeutic strategies for FRDA are years away, the findings 
presented in this dissertation provide valuable information in developing such therapies.  This 
thesis provides novel insights into the role of mitochondrial dynamics in FRDA, begins to detail 
the mechanisms of action for two potentially therapeutic peptides in FRDA models, and suggests 





# Joseph Johnson 
# October 19, 2020 
# Doctoral Dissertation in Pharmacology at the University of Pennsylvan
ia 
# Appendix 1 
 
# This code queries the GSE104288 database first published by Napierala 
et al 2017, PMID: 32291635. 
# The dataset contains normalized RNA transcript levels from fibroblast
s derived from 
# 17 healthy controls and 18 FRDA patients. 
 
# Load the necessary packages 
 
library(tidyverse) 
## -- Attaching packages --------------------------------------- tidyve
rse 1.3.0 -- 
## v ggplot2 3.3.0     v purrr   0.3.4 
## v tibble  3.0.0     v dplyr   0.8.5 
## v tidyr   1.0.2     v stringr 1.4.0 
## v readr   1.3.1     v forcats 0.5.0 
## -- Conflicts ------------------------------------------ tidyverse_co
nflicts() -- 
## x dplyr::filter() masks stats::filter() 
## x dplyr::lag()    masks stats::lag() 
## x dplyr::recode() masks car::recode() 
## x purrr::some()   masks car::some() 
library(GEOquery) 
## Loading required package: Biobase 
## Loading required package: BiocGenerics 
## Loading required package: parallel 
##  
## Attaching package: 'BiocGenerics' 
## The following objects are masked from 'package:parallel': 
##  
##     clusterApply, clusterApplyLB, clusterCall, clusterEvalQ, 
##     clusterExport, clusterMap, parApply, parCapply, parLapply, 
##     parLapplyLB, parRapply, parSapply, parSapplyLB 
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## The following objects are masked from 'package:dplyr': 
##  
##     combine, intersect, setdiff, union 
## The following objects are masked from 'package:stats': 
##  
##     IQR, mad, sd, var, xtabs 
## The following objects are masked from 'package:base': 
##  
##     anyDuplicated, append, as.data.frame, basename, cbind, colnames, 
##     dirname, do.call, duplicated, eval, evalq, Filter, Find, get, gr
ep, 
##     grepl, intersect, is.unsorted, lapply, Map, mapply, match, mget, 
##     order, paste, pmax, pmax.int, pmin, pmin.int, Position, rank, 
##     rbind, Reduce, rownames, sapply, setdiff, sort, table, tapply, 
##     union, unique, unsplit, which, which.max, which.min 
## Welcome to Bioconductor 
##  
##     Vignettes contain introductory material; view with 
##     'browseVignettes()'. To cite Bioconductor, see 
##     'citation("Biobase")', and for packages 'citation("pkgname")'. 
## Setting options('download.file.method.GEOquery'='auto') 
## Setting options('GEOquery.inmemory.gpl'=FALSE) 
library(GEOmetadb) 
## Loading required package: RSQLite 
library(BiocFileCache) 
## Loading required package: dbplyr 
##  
## Attaching package: 'dbplyr' 
## The following objects are masked from 'package:dplyr': 
##  
##     ident, sql 
# Display the metadata 
 
gse104288 <- getGEO("GSE104288", GSEMatrix = TRUE) 




## Parsed with column specification: 
## cols( 
##   .default = col_character() 
## ) 
## See spec(...) for full column specifications. 




## ExpressionSet (storageMode: lockedEnvironment) 
## assayData: 0 features, 35 samples  
##   element names: exprs  
## protocolData: none 
## phenoData 
##   sampleNames: GSM2794401 GSM2794402 ... GSM2794435 (35 total) 
##   varLabels: title geo_accession ... tissue:ch1 (44 total) 
##   varMetadata: labelDescription 
## featureData: none 
## experimentData: use 'experimentData(object)' 
##   pubMedIds: 29125828 
## 31665133 
## 32291635  
## Annotation: GPL11154 
show(pData(phenoData(gse104288[[1]]))[1:35,c(1,10,12)]) 
##             title           characteristics_ch1 characteristics_ch1.
2 
## GSM2794401  C1650             genotype: Control    sampling age: 37 
y 
## GSM2794402  C2036             genotype: Control    sampling age: 11 
y 
## GSM2794403  C2153             genotype: Control    sampling age: 40 
y 
## GSM2794404  C2169             genotype: Control    sampling age: 52 
y 
## GSM2794405 C21808             genotype: Control     sampling age: 1 
d 
## GSM2794406  C2671             genotype: Control    sampling age: 47 
y 
## GSM2794407   C288             genotype: Control    sampling age: 64 
y 




## GSM2794409  C3652             genotype: Control    sampling age: 24 
y 
## GSM2794410  C3956             genotype: Control    sampling age: 27 
y 
## GSM2794411  C5879             genotype: Control    sampling age: 48 
y 
## GSM2794412  C7492             genotype: Control    sampling age: 17 
y 
## GSM2794413  C7522             genotype: Control    sampling age: 19 
y 
## GSM2794414  C7525             genotype: Control    sampling age: 22 
y 
## GSM2794415  C8399             genotype: Control    sampling age: 19 
y 
## GSM2794416   C_UF             genotype: Control    sampling age: 35 
y 
## GSM2794417   C_UM             genotype: Control    sampling age: 39 
y 
## GSM2794418   F130 genotype: Friedreich's ataxia    sampling age: 56 
y 
## GSM2794419   F156 genotype: Friedreich's ataxia    sampling age: 41 
y 
## GSM2794420   F188 genotype: Friedreich's ataxia    sampling age: 47 
y 
## GSM2794421   F203 genotype: Friedreich's ataxia    sampling age: 31 
y 
## GSM2794422   F281 genotype: Friedreich's ataxia    sampling age: 19 
y 
## GSM2794423  F3665 genotype: Friedreich's ataxia    sampling age: 13 
y 
## GSM2794424  F4078 genotype: Friedreich's ataxia    sampling age: 30 
y 
## GSM2794425  F4192 genotype: Friedreich's ataxia    sampling age: 33 
y 
## GSM2794426  F4230 genotype: Friedreich's ataxia    sampling age: 28 
y 
## GSM2794427  F4259 genotype: Friedreich's ataxia    sampling age: 37 
y 
## GSM2794428  F4497 genotype: Friedreich's ataxia    sampling age: 44 
y 
## GSM2794429  F4509 genotype: Friedreich's ataxia    sampling age: 36 
y 
## GSM2794430  F4627 genotype: Friedreich's ataxia    sampling age: 50 
y 
## GSM2794431  F4654 genotype: Friedreich's ataxia    sampling age: 19 
y 




## GSM2794433    F66 genotype: Friedreich's ataxia    sampling age: 70 
y 
## GSM2794434    F68 genotype: Friedreich's ataxia    sampling age: 21 
y 
## GSM2794435    F88 genotype: Friedreich's ataxia    sampling age: 50 
y 
# Read the dataset and title it "GE" 
 
GeneExpressionTable <- read.table("GSE104288_DESeq_counts.txt", header 
= TRUE, sep = "\t") 
GE <- as_tibble(GeneExpressionTable) 
 
# To validate that this code functions properly, the levels of FXN and 
ISCU transcripts were investigated 
# since it is well established that these proteins are downregulated in 
FRDA patients. 
# Indeed, both FXN and ISCU transcripts are significantly decresed in F
RDA patients 
# when running this code on the GSE104288 database. 
 
# FXN Levels 
FXNLevels <- filter(GE, gene=="FXN") 
ControlGroupFXN <- select(FXNLevels, starts_with("C")) 
FAGroupFXN <- select(FXNLevels, starts_with("F")) 
 
t.test(ControlGroupFXN, FAGroupFXN, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupFXN and FAGroupFXN 
## t = 10.532, df = 32.666, p-value = 4.915e-12 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  61.54421 91.02898 
## sample estimates: 
## mean of x mean of y  
## 135.53147  59.24487 
sd(ControlGroupFXN)/sqrt(length(ControlGroupFXN)) 
## [1] 5.299988 
sd(FAGroupFXN)/sqrt(length(FAGroupFXN)) 





ISCULevels <- filter(GE, gene=="ISCU") 
ControlGroupISCU <- select(ISCULevels, starts_with("C")) 
FAGroupISCU <- select(ISCULevels, starts_with("F")) 
 
t.test(ControlGroupISCU, FAGroupISCU, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupISCU and FAGroupISCU 
## t = 2.4885, df = 25.716, p-value = 0.01964 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##   84.40447 888.31498 
## sample estimates: 
## mean of x mean of y  
##  2402.204  1915.844 
# As RTA-408 (omaveloxolone) inhibits KEAP1 from ubiquitinating Nrf2, 
# the levels of KEAP1 and Nrf2 transcripts were examined. 
 
# KEAP1 Levels 
 
KEAP1Levels <- filter(GE, gene=="KEAP1") 
ControlGroupKEAP1 <- select(KEAP1Levels, starts_with("C")) 
FAGroupKEAP1 <- select(KEAP1Levels, starts_with("F")) 
 
t.test(ControlGroupKEAP1, FAGroupKEAP1, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupKEAP1 and FAGroupKEAP1 
## t = 0.97753, df = 32.179, p-value = 0.3356 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -43.41189 123.55907 
## sample estimates: 
## mean of x mean of y  
##  1647.714  1607.640 
sd(ControlGroupKEAP1)/sqrt(length(ControlGroupKEAP1)) 




## [1] 27.04746 
# Nrf2 Levels (endoded by NFE2L2) 
 
Nrf2Levels <- filter(GE, gene=="NFE2L2") 
ControlGroupNrf2 <- select(Nrf2Levels, starts_with("C")) 
FAGroupNrf2 <- select(Nrf2Levels, starts_with("F")) 
 
t.test(ControlGroupNrf2, FAGroupNrf2, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupNrf2 and FAGroupNrf2 
## t = 2.0398, df = 32.509, p-value = 0.04957 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##    0.4062241 405.4493682 
## sample estimates: 
## mean of x mean of y  
##  2117.697  1914.769 
sd(ControlGroupNrf2)/sqrt(length(ControlGroupNrf2)) 
## [1] 64.73632 
sd(FAGroupNrf2)/sqrt(length(FAGroupNrf2)) 
## [1] 75.54224 
# Although Nrf2 transcript levels are decreased, KEAP1 transcript level
s are unaffected. 
# It is therefore possible that Nrf2 is further regulated by another E3 
ubiquitin ligase in FRDA. 
# To examine this, Hrd1 trancript levels were investigated. 
 
 
# Hrd1 Levels (encoded by SYVN1) 
 
SYVN1Levels <- filter(GE, gene=="SYVN1") 
ControlGroupSYVN1 <- select(SYVN1Levels, starts_with("C")) 
FAGroupSYVN1 <- select(SYVN1Levels, starts_with("F")) 
 
t.test(ControlGroupSYVN1, FAGroupSYVN1, alternative = "two.sided",  




##  Welch Two Sample t-test 
##  
## data:  ControlGroupSYVN1 and FAGroupSYVN1 
## t = -3.309, df = 32.757, p-value = 0.002283 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -162.83909  -38.81807 
## sample estimates: 
## mean of x mean of y  
##  336.6194  437.4480 
# Indeed, Hrd1 levels are significantly increased in FRDA patients. 
# It is therefore conceivable that Hrd1 plays a larger role in Nrf2 dow
nregulation 
# in FRDA patients than KEAP1. 
# This suggests that an Hrd1 inhibitor, like LS-102, may be more benefi
cial for FRDA patients 
# than a KEAP1 inhibitor/Nrf2 acitvator like RTA-408 
 
 
# Transcript levels of Drp1 are unchanged in FRDA patients. 
# This further validates that Drp1 protein levels are unchanged in FRDA 
patient fibroblasts; 
# rather, FRDA patients exhibit increased Drp1 clustering at the mitoch
ondria. 
 
#Drp1 Levels (encoded by gene DNM1L) 
 
DNM1LLevels <- filter(GE, gene=="DNM1L") 
ControlGroupDNM1L <- select(DNM1LLevels, starts_with("C")) 
FAGroupDNM1L <- select(DNM1LLevels, starts_with("F")) 
 
t.test(ControlGroupDNM1L, FAGroupDNM1L, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupDNM1L and FAGroupDNM1L 
## t = -0.75214, df = 29.524, p-value = 0.4579 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -269.0664  124.2946 
## sample estimates: 
## mean of x mean of y  




## [1] 77.9672 
sd(FAGroupDNM1L)/sqrt(length(FAGroupDNM1L)) 
## [1] 56.41979 
# CDK1 phosphorylates Drp1 at Ser616, activating the latter protein's G
TPase activity. 




CDK1Levels <- filter(GE, gene=="CDK1") 
ControlGroupCDK1 <- select(CDK1Levels, starts_with("C")) 
FAGroupCDK1 <- select(CDK1Levels, starts_with("F")) 
 
t.test(ControlGroupCDK1, FAGroupCDK1, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupCDK1 and FAGroupCDK1 
## t = -2.9291, df = 17.816, p-value = 0.009033 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -1332.9735  -218.9957 
## sample estimates: 
## mean of x mean of y  
##  293.4558 1069.4404 
sd(ControlGroupCDK1)/sqrt(length(ControlGroupCDK1)) 
## [1] 40.59105 
sd(FAGroupCDK1)/sqrt(length(FAGroupCDK1)) 
## [1] 261.7923 
# Mcl1 chpaerones Drp1 to the mitochondria. 
# Atlhough Mcl1 protiens levels are increased in FXN knockdown fibrobla
sts, 
# Mcl1 transcript levels are unaffected in FRDA patients. 
# This may reflect an inherent difference between sub-acute and chronic 
FRDA models 
# or Mcl1 protein levels may be regulated post-transcription. 
 




Mcl1Levels <- filter(GE, gene=="MCL1") 
ControlGroupMcl1 <- select(Mcl1Levels, starts_with("C")) 
FAGroupMcl1 <- select(Mcl1Levels, starts_with("F")) 
 
t.test(ControlGroupMcl1, FAGroupMcl1, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupMcl1 and FAGroupMcl1 
## t = -0.51358, df = 24.953, p-value = 0.6121 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -1337.5235   803.6366 
## sample estimates: 
## mean of x mean of y  
##  6834.972  7101.915 
sd(ControlGroupMcl1)/sqrt(length(ControlGroupMcl1)) 
## [1] 233.0554 
sd(FAGroupMcl1)/sqrt(length(FAGroupMcl1)) 
## [1] 464.5882 
# OPA1 regulates fusion of the inner mitochondrial membrane. 




OPA1Levels <- filter(GE, gene=="OPA1") 
ControlGroupOPA1 <- select(OPA1Levels, starts_with("C")) 
FAGroupOPA1 <- select(OPA1Levels, starts_with("F")) 
 
t.test(ControlGroupOPA1, FAGroupOPA1, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupOPA1 and FAGroupOPA1 
## t = -1.94, df = 29.599, p-value = 0.06197 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -309.473225    8.038691 
## sample estimates: 
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## mean of x mean of y  
##  2016.318  2167.035 
# PGC1B plays a critical role in mitochondrial biogenesis. 
# Transcript levels of this protein are significantly increased in FRDA 
patients 
# suggesting that patient cells may attempt to compensate for mitochond
rial dysfunction 
# by upregulating mitochondrial biogenesis. 
 
#PGC1beta Levels (encoded by gene PPARGC1B) 
 
PGC1BLevels <- filter(GE, gene=="PPARGC1B") 
ControlGroupPGC1B <- select(PGC1BLevels, starts_with("C")) 
FAGroupPGC1B <- select(PGC1BLevels, starts_with("F")) 
 
t.test(ControlGroupPGC1B, FAGroupPGC1B, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupPGC1B and FAGroupPGC1B 
## t = -3.2499, df = 22.256, p-value = 0.003635 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -25.074894  -5.547094 
## sample estimates: 
## mean of x mean of y  
##  9.066452 24.377446 
sd(ControlGroupPGC1B)/sqrt(length(ControlGroupPGC1B)) 
## [1] 1.74763 
sd(FAGroupPGC1B)/sqrt(length(FAGroupPGC1B)) 
## [1] 4.375054 
# Transcript levels of NFKB1, a subunit of the master transcriptional r
egulator NF-kB, 
# are signfiicantly decerased in FRDA patients. 
 
# NFKB1 Levels 
 
NFKB1Levels <- filter(GE, gene=="NFKB1") 
ControlGroupNFKB1 <- select(NFKB1Levels, starts_with("C")) 




t.test(ControlGroupNFKB1, FAGroupNFKB1, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupNFKB1 and FAGroupNFKB1 
## t = 3.0303, df = 32.893, p-value = 0.004733 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  102.5824 521.9362 
## sample estimates: 
## mean of x mean of y  
##  1660.805  1348.546 
# NLRP12 is involved in inflammasome activation. 
# NLRP12 transcript levels are significantly increased in FRDA patients
, 
# suggesting a potential role of inflammasome activation in FRDA. 
 
# NLRP12 levels 
 
NLRP12Levels <- filter(GE, gene=="NLRP12") 
ControlGroupNLRP12 <- select(NLRP12Levels, starts_with("C")) 
FAGroupNLRP12 <- select(NLRP12Levels, starts_with("F")) 
 
t.test(ControlGroupNLRP12, FAGroupNLRP12, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupNLRP12 and FAGroupNLRP12 
## t = -2.9393, df = 26.556, p-value = 0.00673 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -17.01404  -3.01884 
## sample estimates: 
## mean of x mean of y  
##  28.90673  38.92317 
# The following protein transcripts did not show a significant differen
ce in FRDA patients. 
# They were investigated because of their potential involvement in mito
chondrial dysfunctions in FRDA. 
 
# BTRC Levels 
 
BTRCLevels <- filter(GE, gene=="BTRC") 
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ControlGroupBTRC <- select(BTRCLevels, starts_with("C")) 
FAGroupBTRC <- select(BTRCLevels, starts_with("F")) 
 
t.test(ControlGroupBTRC, FAGroupBTRC, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupBTRC and FAGroupBTRC 
## t = 0.26411, df = 27.759, p-value = 0.7936 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -36.06449  46.73610 
## sample estimates: 
## mean of x mean of y  
##  450.5744  445.2386 
# NFKB2 Levels 
NFKB2Levels <- filter(GE, gene=="NFKB2") 
ControlGroupNFKB2 <- select(NFKB2Levels, starts_with("C")) 
FAGroupNFKB2 <- select(NFKB2Levels, starts_with("F")) 
 
t.test(ControlGroupNFKB2, FAGroupNFKB2, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupNFKB2 and FAGroupNFKB2 
## t = -1.7903, df = 28.82, p-value = 0.08392 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -136.415563    9.084809 
## sample estimates: 
## mean of x mean of y  
##  437.0860  500.7513 
# IL1B Levels 
 
IL1BLevels <- filter(GE, gene=="IL1B") 
ControlGroupIL1B <- select(IL1BLevels, starts_with("C")) 
FAGroupIL1B <- select(IL1BLevels, starts_with("F")) 
 
t.test(ControlGroupIL1B, FAGroupIL1B, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  




## data:  ControlGroupIL1B and FAGroupIL1B 
## t = -1.1096, df = 19.076, p-value = 0.2809 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -27.762889   8.521311 
## sample estimates: 
## mean of x mean of y  
##  7.336399 16.957188 
# NLRP1 levels 
 
NLRP1Levels <- filter(GE, gene=="NLRP1") 
ControlGroupNLRP1 <- select(NLRP1Levels, starts_with("C")) 
FAGroupNLRP1 <- select(NLRP1Levels, starts_with("F")) 
 
t.test(ControlGroupNLRP1, FAGroupNLRP1, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupNLRP1 and FAGroupNLRP1 
## t = -1.3833, df = 31.664, p-value = 0.1762 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -252.73187   48.34702 
## sample estimates: 
## mean of x mean of y  
##  769.1020  871.2945 
# NLRP10 levels 
 
NLRP10Levels <- filter(GE, gene=="NLRP10") 
ControlGroupNLRP10 <- select(NLRP10Levels, starts_with("C")) 
FAGroupNLRP10 <- select(NLRP10Levels, starts_with("F")) 
 
t.test(ControlGroupNLRP10, FAGroupNLRP10, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupNLRP10 and FAGroupNLRP10 
## t = 0.28626, df = 31.043, p-value = 0.7766 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -28.51824  37.83148 
## sample estimates: 
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## mean of x mean of y  
##  60.24652  55.58989 
#PGC1alpha Levels (encoded by gene PPARGC1A) 
 
PGC1ALevels <- filter(GE, gene=="PPARGC1A") 
ControlGroupPGC1A <- select(PGC1ALevels, starts_with("C")) 
FAGroupPGC1A <- select(PGC1ALevels, starts_with("F")) 
 
t.test(ControlGroupPGC1A, FAGroupPGC1A, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupPGC1A and FAGroupPGC1A 
## t = -0.76971, df = 32.264, p-value = 0.4471 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -67.46503  30.45243 
## sample estimates: 
## mean of x mean of y  
##  56.07191  74.57821 
# Tid1 Levels (encoded by the gene DNAJA3) 
 
TID1Levels <- filter(GE, gene=="DNAJA3") 
ControlGroupTID1 <- select(TID1Levels, starts_with("C")) 
FAGroupTID1 <- select(TID1Levels, starts_with("F")) 
 
t.test(ControlGroupTID1, FAGroupTID1, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupTID1 and FAGroupTID1 
## t = 1.3818, df = 31.216, p-value = 0.1768 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -29.29669 152.49997 
## sample estimates: 
## mean of x mean of y  
##  990.2590  928.6574 
# GRP75 Levels (encoded by the gene HSPA9) 
 
GRP75Levels <- filter(GE, gene=="HSPA9") 
ControlGroupGRP75 <- select(GRP75Levels, starts_with("C")) 
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FAGroupGRP75 <- select(GRP75Levels, starts_with("F")) 
 
t.test(ControlGroupGRP75, FAGroupGRP75, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupGRP75 and FAGroupGRP75 
## t = 0.25178, df = 32.964, p-value = 0.8028 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -1019.199  1307.076 
## sample estimates: 
## mean of x mean of y  
##  7061.775  6917.836 
# Pink1 Levels 
 
PINK1Levels <- filter(GE, gene=="PINK1") 
ControlGroupPINK1 <- select(PINK1Levels, starts_with("C")) 
FAGroupPINK1 <- select(PINK1Levels, starts_with("F")) 
 
t.test(ControlGroupPINK1, FAGroupPINK1, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupPINK1 and FAGroupPINK1 
## t = -1.1071, df = 21.778, p-value = 0.2803 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -723.4902  220.0691 
## sample estimates: 
## mean of x mean of y  
##  2660.809  2912.520 
# PPARG Levels 
 
PPARGLevels <- filter(GE, gene=="PPARG") 
ControlGroupPPARG <- select(PPARGLevels, starts_with("C")) 
FAGroupPPARG <- select(PPARGLevels, starts_with("F")) 
 
t.test(ControlGroupPPARG, FAGroupPPARG, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  




## data:  ControlGroupPPARG and FAGroupPPARG 
## t = -1.6196, df = 30.611, p-value = 0.1156 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -201.38498   23.16314 
## sample estimates: 
## mean of x mean of y  
##  151.5573  240.6683 
# TFAM Levels 
TFAMLevels <- filter(GE, gene=="TFAM") 
ControlGroupTFAM <- select(TFAMLevels, starts_with("C")) 
FAGroupTFAM <- select(TFAMLevels, starts_with("F")) 
 
t.test(ControlGroupTFAM, FAGroupTFAM, alternative = "two.sided",  
       mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95) 
##  
##  Welch Two Sample t-test 
##  
## data:  ControlGroupTFAM and FAGroupTFAM 
## t = -0.15532, df = 32.998, p-value = 0.8775 
## alternative hypothesis: true difference in means is not equal to 0 
## 95 percent confidence interval: 
##  -64.01809  54.93694 
## sample estimates: 
## mean of x mean of y  
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